CR2Cancer

Summary
Symbol	SIRT1
Name	sirtuin 1
Aliases	SIR2L1; sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 1; sirtuin (silent mat ......
Location	10q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Domain, Function and Classification > Gene Ontology > KEGG and Reactome Pathway

> Domain, Function and Classification

[ TOP ]

Domain

PF02146 Sir2 family

Function

NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cell cycle, response to DNA damage, metobolism, apoptosis and autophagy. Can modulate chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. Deacetylates a broad range of transcription factors and coregulators, thereby regulating target gene expression positively and negatively. Serves as a sensor of the cytosolic ratio of NAD(+)/NADH which is altered by glucose deprivation and metabolic changes associated with caloric restriction. Is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5'-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT). Component of the eNoSC (energy-dependent nucleolar silencing) complex, a complex that mediates silencing of rDNA in response to intracellular energy status and acts by recruiting histone-modifying enzymes. The eNoSC complex is able to sense the energy status of cell: upon glucose starvation, elevation of NAD(+)/NADP(+) ratio activates SIRT1, leading to histone H3 deacetylation followed by dimethylation of H3 at 'Lys-9' (H3K9me2) by SUV39H1 and the formation of silent chromatin in the rDNA locus. Deacetylates 'Lys-266' of SUV39H1, leading to its activation. Inhibits skeletal muscle differentiation by deacetylating PCAF and MYOD1. Deacetylates H2A and 'Lys-26' of HIST1H1E. Deacetylates 'Lys-16' of histone H4 (in vitro). Involved in NR0B2/SHP corepression function through chromatin remodeling: Recruited to LRH1 target gene promoters by NR0B2/SHP thereby stimulating histone H3 and H4 deacetylation leading to transcriptional repression. Proposed to contribute to genomic integrity via positive regulation of telomere length; however, reports on localization to pericentromeric heterochromatin are conflicting. Proposed to play a role in constitutive heterochromatin (CH) formation and/or maintenance through regulation of the available pool of nuclear SUV39H1. Upon oxidative/metabolic stress decreases SUV39H1 degradation by inhibiting SUV39H1 polyubiquitination by MDM2. This increase in SUV39H1 levels enhances SUV39H1 turnover in CH, which in turn seems to accelerate renewal of the heterochromatin which correlates with greater genomic integrity during stress response. Deacetylates 'Lys-382' of p53/TP53 and impairs its ability to induce transcription-dependent proapoptotic program and modulate cell senescence. Deacetylates TAF1B and thereby represses rDNA transcription by the RNA polymerase I. Deacetylates MYC, promotes the association of MYC with MAX and decreases MYC stability leading to compromised transformational capability. Deacetylates FOXO3 in response to oxidative stress thereby increasing its ability to induce cell cycle arrest and resistance to oxidative stress but inhibiting FOXO3-mediated induction of apoptosis transcriptional activity; also leading to FOXO3 ubiquitination and protesomal degradation. Appears to have a similar effect on MLLT7/FOXO4 in regulation of transcriptional activity and apoptosis. Deacetylates DNMT1; thereby impairs DNMT1 methyltransferase-independent transcription repressor activity, modulates DNMT1 cell cycle regulatory function and DNMT1-mediated gene silencing. Deacetylates RELA/NF-kappa-B p65 thereby inhibiting its transactivating potential and augments apoptosis in response to TNF-alpha. Deacetylates HIF1A, KAT5/TIP60, RB1 and HIC1. Deacetylates FOXO1 resulting in its nuclear retention and enhancement of its transcriptional activity leading to increased gluconeogenesis in liver. Inhibits E2F1 transcriptional activity and apoptotic function, possibly by deacetylation. Involved in HES1- and HEY2-mediated transcriptional repression. In cooperation with MYCN seems to be involved in transcriptional repression of DUSP6/MAPK3 leading to MYCN stabilization by phosphorylation at 'Ser-62'. Deacetylates MEF2D. Required for antagonist-mediated transcription suppression of AR-dependent genes which may be linked to local deacetylation of histone H3. Represses HNF1A-mediated transcription. Required for the repression of ESRRG by CREBZF. Modulates AP-1 transcription factor activity. Deacetylates NR1H3 AND NR1H2 and deacetylation of NR1H3 at 'Lys-434' positively regulates transcription of NR1H3:RXR target genes, promotes NR1H3 proteosomal degradation and results in cholesterol efflux; a promoter clearing mechanism after reach round of transcription is proposed. Involved in lipid metabolism. Implicated in regulation of adipogenesis and fat mobilization in white adipocytes by repression of PPARG which probably involves association with NCOR1 and SMRT/NCOR2. Deacetylates ACSS2 leading to its activation, and HMGCS1. Involved in liver and muscle metabolism. Through deacteylation and activation of PPARGC1A is required to activate fatty acid oxidation in skeletel muscle under low-glucose conditions and is involved in glucose homeostasis. Involved in regulation of PPARA and fatty acid beta-oxidation in liver. Involved in positive regulation of insulin secretion in pancreatic beta cells in response to glucose; the function seems to imply transcriptional repression of UCP2. Proposed to deacetylate IRS2 thereby facilitating its insulin-induced tyrosine phosphorylation. Deacetylates SREBF1 isoform SREBP-1C thereby decreasing its stability and transactivation in lipogenic gene expression. Involved in DNA damage response by repressing genes which are involved in DNA repair, such as XPC and TP73, deacetylating XRCC6/Ku70, and faciliting recruitment of additional factors to sites of damaged DNA, such as SIRT1-deacetylated NBN can recruit ATM to initiate DNA repair and SIRT1-deacetylated XPA interacts with RPA2. Also involved in DNA repair of DNA double-strand breaks by homologous recombination and specifically single-strand annealing independently of XRCC6/Ku70 and NBN. Transcriptional suppression of XPC probably involves an E2F4:RBL2 suppressor complex and protein kinase B (AKT) signaling. Transcriptional suppression of TP73 probably involves E2F4 and PCAF. Deacetylates WRN thereby regulating its helicase and exonuclease activities and regulates WRN nuclear translocation in response to DNA damage. Deacetylates APEX1 at 'Lys-6' and 'Lys-7' and stimulates cellular AP endonuclease activity by promoting the association of APEX1 to XRCC1. Increases p53/TP53-mediated transcription-independent apoptosis by blocking nuclear translocation of cytoplasmic p53/TP53 and probably redirecting it to mitochondria. Deacetylates XRCC6/Ku70 at 'Lys-539' and 'Lys-542' causing it to sequester BAX away from mitochondria thereby inhibiting stress-induced apoptosis. Is involved in autophagy, presumably by deacetylating ATG5, ATG7 and MAP1LC3B/ATG8. Deacetylates AKT1 which leads to enhanced binding of AKT1 and PDK1 to PIP3 and promotes their activation. Proposed to play role in regulation of STK11/LBK1-dependent AMPK signaling pathways implicated in cellular senescence which seems to involve the regulation of the acetylation status of STK11/LBK1. Can deacetylate STK11/LBK1 and thereby increase its activity, cytoplasmic localization and association with STRAD; however, the relevance of such activity in normal cells is unclear. In endothelial cells is shown to inhibit STK11/LBK1 activity and to promote its degradation. Deacetylates SMAD7 at 'Lys-64' and 'Lys-70' thereby promoting its degradation. Deacetylates CIITA and augments its MHC class II transactivation and contributes to its stability. Deacteylates MECOM/EVI1. Deacetylates PML at 'Lys-487' and this deacetylation promotes PML control of PER2 nuclear localization. During the neurogenic transition, repress selective NOTCH1-target genes through histone deacetylation in a BCL6-dependent manner and leading to neuronal differentiation. Regulates the circadian expression of several core clock genes, including ARNTL/BMAL1, RORC, PER2 and CRY1 and plays a critical role in maintaining a controlled rhythmicity in histone acetylation, thereby contributing to circadian chromatin remodeling. Deacetylates ARNTL/BMAL1 and histones at the circadian gene promoters in order to facilitate repression by inhibitory components of the circadian oscillator. Deacetylates PER2, facilitating its ubiquitination and degradation by the proteosome. Protects cardiomyocytes against palmitate-induced apoptosis (PubMed:11672523, PubMed:12006491, PubMed:14976264, PubMed:14980222, PubMed:15126506, PubMed:15152190, PubMed:15205477, PubMed:15469825, PubMed:15692560, PubMed:16079181, PubMed:16166628, PubMed:16892051, PubMed:16998810, PubMed:17283066, PubMed:17334224, PubMed:17505061, PubMed:17612497, PubMed:17620057, PubMed:17936707, PubMed:18203716, PubMed:18296641, PubMed:18662546, PubMed:18687677, PubMed:19188449, PubMed:19220062, PubMed:19364925, PubMed:19690166, PubMed:19934257, PubMed:20097625, PubMed:20100829, PubMed:20203304, PubMed:20375098, PubMed:20620956, PubMed:20670893, PubMed:20817729, PubMed:21149730, PubMed:21245319, PubMed:21471201, PubMed:21504832, PubMed:21555002, PubMed:21698133, PubMed:21701047, PubMed:21775285, PubMed:21807113, PubMed:21841822, PubMed:21890893, PubMed:21909281, PubMed:21947282, PubMed:22274616). Deacetylates XBP1 isoform 2; deacetylation decreases protein stability of XBP1 isoform 2 and inhibits its transcriptional activity (PubMed:20955178). Involved in the CCAR2-mediated regulation of PCK1 and NR1D1 (PubMed:24415752). Deacetylates CTNB1 at 'Lys-49' (PubMed:24824780). In POMC (pro-opiomelanocortin) neurons, required for leptin-induced activation of PI3K signaling (By similarity). ; FUNCTION: Isoform 2: Isoform 2 is shown to deacetylate 'Lys-382' of p53/TP53, however with lower activity than isoform 1. In combination, the two isoforms exert an additive effect. Isoform 2 regulates p53/TP53 expression and cellular stress response and is in turn repressed by p53/TP53 presenting a SIRT1 isoform-dependent auto-regulatory loop. ; FUNCTION: (Microbial infection) In case of HIV-1 infection, interacts with and deacetylates the viral Tat protein. The viral Tat protein inhibits SIRT1 deacetylation activity toward RELA/NF-kappa-B p65, thereby potentiates its transcriptional activity and SIRT1 is proposed to contribute to T-cell hyperactivation during infection. ; FUNCTION: SirtT1 75 kDa fragment: catalytically inactive 75SirT1 may be involved in regulation of apoptosis. May be involved in protecting chondrocytes from apoptotic death by associating with cytochrome C and interfering with apoptosome assembly.

Classification

Class	Modification	Substrate	Product	PubMed
Histone modification erase, Histone modification write cofactor	Histone acetylation, Histone methylation	H1K26ac, H3K9ac, H4K16ac	H1K26, H3K9, H4K16	15469825

> Gene Ontology [ TOP ]
Biological Process	GO:0000012 single strand break repair GO:0000060 protein import into nucleus, translocation GO:0000183 chromatin silencing at rDNA GO:0000302 response to reactive oxygen species GO:0000720 pyrimidine dimer repair by nucleotide-excision repair GO:0000731 DNA synthesis involved in DNA repair GO:0001516 prostaglandin biosynthetic process GO:0001525 angiogenesis GO:0001542 ovulation from ovarian follicle GO:0001558 regulation of cell growth GO:0001666 response to hypoxia GO:0001678 cellular glucose homeostasis GO:0001933 negative regulation of protein phosphorylation GO:0001935 endothelial cell proliferation GO:0001936 regulation of endothelial cell proliferation GO:0001938 positive regulation of endothelial cell proliferation GO:0002250 adaptive immune response GO:0002367 cytokine production involved in immune response GO:0002440 production of molecular mediator of immune response GO:0002521 leukocyte differentiation GO:0002573 myeloid leukocyte differentiation GO:0002819 regulation of adaptive immune response GO:0002821 positive regulation of adaptive immune response GO:0005996 monosaccharide metabolic process GO:0006006 glucose metabolic process GO:0006109 regulation of carbohydrate metabolic process GO:0006260 DNA replication GO:0006282 regulation of DNA repair GO:0006289 nucleotide-excision repair GO:0006290 pyrimidine dimer repair GO:0006342 chromatin silencing GO:0006343 establishment of chromatin silencing GO:0006344 maintenance of chromatin silencing GO:0006346 methylation-dependent chromatin silencing GO:0006364 rRNA processing GO:0006469 negative regulation of protein kinase activity GO:0006473 protein acetylation GO:0006475 internal protein amino acid acetylation GO:0006476 protein deacetylation GO:0006479 protein methylation GO:0006606 protein import into nucleus GO:0006631 fatty acid metabolic process GO:0006633 fatty acid biosynthetic process GO:0006636 unsaturated fatty acid biosynthetic process GO:0006638 neutral lipid metabolic process GO:0006639 acylglycerol metabolic process GO:0006641 triglyceride metabolic process GO:0006642 triglyceride mobilization GO:0006690 icosanoid metabolic process GO:0006692 prostanoid metabolic process GO:0006693 prostaglandin metabolic process GO:0006694 steroid biosynthetic process GO:0006699 bile acid biosynthetic process GO:0006869 lipid transport GO:0006913 nucleocytoplasmic transport GO:0006914 autophagy GO:0006925 inflammatory cell apoptotic process GO:0006979 response to oxidative stress GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0007179 transforming growth factor beta receptor signaling pathway GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0007283 spermatogenesis GO:0007292 female gamete generation GO:0007346 regulation of mitotic cell cycle GO:0007517 muscle organ development GO:0007548 sex differentiation GO:0007568 aging GO:0007569 cell aging GO:0007623 circadian rhythm GO:0008202 steroid metabolic process GO:0008206 bile acid metabolic process GO:0008213 protein alkylation GO:0008286 insulin receptor signaling pathway GO:0008406 gonad development GO:0008585 female gonad development GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008631 intrinsic apoptotic signaling pathway in response to oxidative stress GO:0009266 response to temperature stimulus GO:0009267 cellular response to starvation GO:0009314 response to radiation GO:0009408 response to heat GO:0009411 response to UV GO:0009416 response to light stimulus GO:0009755 hormone-mediated signaling pathway GO:0009991 response to extracellular stimulus GO:0010035 response to inorganic substance GO:0010212 response to ionizing radiation GO:0010498 proteasomal protein catabolic process GO:0010506 regulation of autophagy GO:0010508 positive regulation of autophagy GO:0010565 regulation of cellular ketone metabolic process GO:0010657 muscle cell apoptotic process GO:0010660 regulation of muscle cell apoptotic process GO:0010675 regulation of cellular carbohydrate metabolic process GO:0010874 regulation of cholesterol efflux GO:0010875 positive regulation of cholesterol efflux GO:0010876 lipid localization GO:0010883 regulation of lipid storage GO:0010906 regulation of glucose metabolic process GO:0010934 macrophage cytokine production GO:0010950 positive regulation of endopeptidase activity GO:0010952 positive regulation of peptidase activity GO:0014065 phosphatidylinositol 3-kinase signaling GO:0014066 regulation of phosphatidylinositol 3-kinase signaling GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling GO:0015850 organic hydroxy compound transport GO:0015918 sterol transport GO:0016049 cell growth GO:0016053 organic acid biosynthetic process GO:0016072 rRNA metabolic process GO:0016236 macroautophagy GO:0016239 positive regulation of macroautophagy GO:0016241 regulation of macroautophagy GO:0016458 gene silencing GO:0016570 histone modification GO:0016571 histone methylation GO:0016573 histone acetylation GO:0016575 histone deacetylation GO:0017015 regulation of transforming growth factor beta receptor signaling pathway GO:0017038 protein import GO:0018022 peptidyl-lysine methylation GO:0018205 peptidyl-lysine modification GO:0018393 internal peptidyl-lysine acetylation GO:0018394 peptidyl-lysine acetylation GO:0019216 regulation of lipid metabolic process GO:0019217 regulation of fatty acid metabolic process GO:0019218 regulation of steroid metabolic process GO:0019318 hexose metabolic process GO:0019915 lipid storage GO:0022602 ovulation cycle process GO:0022613 ribonucleoprotein complex biogenesis GO:0030099 myeloid cell differentiation GO:0030225 macrophage differentiation GO:0030301 cholesterol transport GO:0030308 negative regulation of cell growth GO:0030330 DNA damage response, signal transduction by p53 class mediator GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030518 intracellular steroid hormone receptor signaling pathway GO:0030521 androgen receptor signaling pathway GO:0030522 intracellular receptor signaling pathway GO:0030728 ovulation GO:0031056 regulation of histone modification GO:0031057 negative regulation of histone modification GO:0031058 positive regulation of histone modification GO:0031060 regulation of histone methylation GO:0031062 positive regulation of histone methylation GO:0031392 regulation of prostaglandin biosynthetic process GO:0031393 negative regulation of prostaglandin biosynthetic process GO:0031647 regulation of protein stability GO:0031648 protein destabilization GO:0031667 response to nutrient levels GO:0031668 cellular response to extracellular stimulus GO:0031669 cellular response to nutrient levels GO:0031929 TOR signaling GO:0031935 regulation of chromatin silencing GO:0031937 positive regulation of chromatin silencing GO:0032006 regulation of TOR signaling GO:0032007 negative regulation of TOR signaling GO:0032069 regulation of nuclease activity GO:0032070 regulation of deoxyribonuclease activity GO:0032071 regulation of endodeoxyribonuclease activity GO:0032088 negative regulation of NF-kappaB transcription factor activity GO:0032259 methylation GO:0032368 regulation of lipid transport GO:0032370 positive regulation of lipid transport GO:0032371 regulation of sterol transport GO:0032373 positive regulation of sterol transport GO:0032374 regulation of cholesterol transport GO:0032376 positive regulation of cholesterol transport GO:0032386 regulation of intracellular transport GO:0032868 response to insulin GO:0032869 cellular response to insulin stimulus GO:0032922 circadian regulation of gene expression GO:0033028 myeloid cell apoptotic process GO:0033032 regulation of myeloid cell apoptotic process GO:0033034 positive regulation of myeloid cell apoptotic process GO:0033143 regulation of intracellular steroid hormone receptor signaling pathway GO:0033144 negative regulation of intracellular steroid hormone receptor signaling pathway GO:0033157 regulation of intracellular protein transport GO:0033158 regulation of protein import into nucleus, translocation GO:0033210 leptin-mediated signaling pathway GO:0033344 cholesterol efflux GO:0033500 carbohydrate homeostasis GO:0033559 unsaturated fatty acid metabolic process GO:0033574 response to testosterone GO:0033673 negative regulation of kinase activity GO:0033674 positive regulation of kinase activity GO:0034390 smooth muscle cell apoptotic process GO:0034391 regulation of smooth muscle cell apoptotic process GO:0034470 ncRNA processing GO:0034504 protein localization to nucleus GO:0034599 cellular response to oxidative stress GO:0034605 cellular response to heat GO:0034612 response to tumor necrosis factor GO:0034614 cellular response to reactive oxygen species GO:0034644 cellular response to UV GO:0034968 histone lysine methylation GO:0034976 response to endoplasmic reticulum stress GO:0034983 peptidyl-lysine deacetylation GO:0035065 regulation of histone acetylation GO:0035067 negative regulation of histone acetylation GO:0035356 cellular triglyceride homeostasis GO:0035357 peroxisome proliferator activated receptor signaling pathway GO:0035358 regulation of peroxisome proliferator activated receptor signaling pathway GO:0035601 protein deacylation GO:0036293 response to decreased oxygen levels GO:0036294 cellular response to decreased oxygen levels GO:0036473 cell death in response to oxidative stress GO:0040029 regulation of gene expression, epigenetic GO:0042180 cellular ketone metabolic process GO:0042254 ribosome biogenesis GO:0042304 regulation of fatty acid biosynthetic process GO:0042306 regulation of protein import into nucleus GO:0042326 negative regulation of phosphorylation GO:0042542 response to hydrogen peroxide GO:0042593 glucose homeostasis GO:0042594 response to starvation GO:0042595 behavioral response to starvation GO:0042632 cholesterol homeostasis GO:0042698 ovulation cycle GO:0042770 signal transduction in response to DNA damage GO:0042771 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043401 steroid hormone mediated signaling pathway GO:0043414 macromolecule methylation GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0043434 response to peptide hormone GO:0043491 protein kinase B signaling GO:0043516 regulation of DNA damage response, signal transduction by p53 class mediator GO:0043518 negative regulation of DNA damage response, signal transduction by p53 class mediator GO:0043543 protein acylation GO:0043966 histone H3 acetylation GO:0043967 histone H4 acetylation GO:0043984 histone H4-K16 acetylation GO:0044154 histone H3-K14 acetylation GO:0044262 cellular carbohydrate metabolic process GO:0044283 small molecule biosynthetic process GO:0044320 cellular response to leptin stimulus GO:0044321 response to leptin GO:0044723 single-organism carbohydrate metabolic process GO:0044744 protein targeting to nucleus GO:0045137 development of primary sexual characteristics GO:0045342 MHC class II biosynthetic process GO:0045346 regulation of MHC class II biosynthetic process GO:0045348 positive regulation of MHC class II biosynthetic process GO:0045444 fat cell differentiation GO:0045598 regulation of fat cell differentiation GO:0045599 negative regulation of fat cell differentiation GO:0045717 negative regulation of fatty acid biosynthetic process GO:0045739 positive regulation of DNA repair GO:0045765 regulation of angiogenesis GO:0045766 positive regulation of angiogenesis GO:0045814 negative regulation of gene expression, epigenetic GO:0045833 negative regulation of lipid metabolic process GO:0045860 positive regulation of protein kinase activity GO:0045862 positive regulation of proteolysis GO:0045922 negative regulation of fatty acid metabolic process GO:0045926 negative regulation of growth GO:0046394 carboxylic acid biosynthetic process GO:0046456 icosanoid biosynthetic process GO:0046457 prostanoid biosynthetic process GO:0046486 glycerolipid metabolic process GO:0046545 development of primary female sexual characteristics GO:0046626 regulation of insulin receptor signaling pathway GO:0046628 positive regulation of insulin receptor signaling pathway GO:0046660 female sex differentiation GO:0046822 regulation of nucleocytoplasmic transport GO:0046890 regulation of lipid biosynthetic process GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0048232 male gamete generation GO:0048511 rhythmic process GO:0048514 blood vessel morphogenesis GO:0048545 response to steroid hormone GO:0048608 reproductive structure development GO:0050673 epithelial cell proliferation GO:0050678 regulation of epithelial cell proliferation GO:0050679 positive regulation of epithelial cell proliferation GO:0050810 regulation of steroid biosynthetic process GO:0050872 white fat cell differentiation GO:0050873 brown fat cell differentiation GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0051055 negative regulation of lipid biosynthetic process GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051095 regulation of helicase activity GO:0051097 negative regulation of helicase activity GO:0051169 nuclear transport GO:0051170 nuclear import GO:0051235 maintenance of location GO:0051346 negative regulation of hydrolase activity GO:0051348 negative regulation of transferase activity GO:0051567 histone H3-K9 methylation GO:0051570 regulation of histone H3-K9 methylation GO:0051574 positive regulation of histone H3-K9 methylation GO:0051896 regulation of protein kinase B signaling GO:0051898 negative regulation of protein kinase B signaling GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:0055088 lipid homeostasis GO:0055089 fatty acid homeostasis GO:0055090 acylglycerol homeostasis GO:0055092 sterol homeostasis GO:0060612 adipose tissue development GO:0060765 regulation of androgen receptor signaling pathway GO:0060766 negative regulation of androgen receptor signaling pathway GO:0060968 regulation of gene silencing GO:0061082 myeloid leukocyte cytokine production GO:0061448 connective tissue development GO:0061458 reproductive system development GO:0061647 histone H3-K9 modification GO:0070059 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress GO:0070301 cellular response to hydrogen peroxide GO:0070328 triglyceride homeostasis GO:0070482 response to oxygen levels GO:0070857 regulation of bile acid biosynthetic process GO:0070914 UV-damage excision repair GO:0070932 histone H3 deacetylation GO:0070997 neuron death GO:0071214 cellular response to abiotic stimulus GO:0071356 cellular response to tumor necrosis factor GO:0071375 cellular response to peptide hormone stimulus GO:0071383 cellular response to steroid hormone stimulus GO:0071394 cellular response to testosterone stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0071417 cellular response to organonitrogen compound GO:0071440 regulation of histone H3-K14 acetylation GO:0071441 negative regulation of histone H3-K14 acetylation GO:0071453 cellular response to oxygen levels GO:0071456 cellular response to hypoxia GO:0071478 cellular response to radiation GO:0071479 cellular response to ionizing radiation GO:0071482 cellular response to light stimulus GO:0071496 cellular response to external stimulus GO:0071559 response to transforming growth factor beta GO:0071560 cellular response to transforming growth factor beta stimulus GO:0071887 leukocyte apoptotic process GO:0071888 macrophage apoptotic process GO:0071897 DNA biosynthetic process GO:0071900 regulation of protein serine/threonine kinase activity GO:0071901 negative regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:0072330 monocarboxylic acid biosynthetic process GO:0072331 signal transduction by p53 class mediator GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway GO:0090239 regulation of histone H4 acetylation GO:0090241 negative regulation of histone H4 acetylation GO:0090287 regulation of cellular response to growth factor stimulus GO:0090288 negative regulation of cellular response to growth factor stimulus GO:0090335 regulation of brown fat cell differentiation GO:0090342 regulation of cell aging GO:0090343 positive regulation of cell aging GO:0090344 negative regulation of cell aging GO:0090398 cellular senescence GO:0090400 stress-induced premature senescence GO:0097193 intrinsic apoptotic signaling pathway GO:0098732 macromolecule deacylation GO:1900034 regulation of cellular response to heat GO:1900076 regulation of cellular response to insulin stimulus GO:1900078 positive regulation of cellular response to insulin stimulus GO:1900180 regulation of protein localization to nucleus GO:1900407 regulation of cellular response to oxidative stress GO:1900408 negative regulation of cellular response to oxidative stress GO:1901214 regulation of neuron death GO:1901215 negative regulation of neuron death GO:1901342 regulation of vasculature development GO:1901652 response to peptide GO:1901653 cellular response to peptide GO:1901654 response to ketone GO:1901655 cellular response to ketone GO:1901796 regulation of signal transduction by p53 class mediator GO:1901797 negative regulation of signal transduction by p53 class mediator GO:1901983 regulation of protein acetylation GO:1901984 negative regulation of protein acetylation GO:1902165 regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:1902166 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:1902175 regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902235 regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902237 positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902253 regulation of intrinsic apoptotic signaling pathway by p53 class mediator GO:1902254 negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator GO:1902275 regulation of chromatin organization GO:1902532 negative regulation of intracellular signal transduction GO:1902593 single-organism nuclear import GO:1902882 regulation of response to oxidative stress GO:1902883 negative regulation of response to oxidative stress GO:1903201 regulation of oxidative stress-induced cell death GO:1903202 negative regulation of oxidative stress-induced cell death GO:1903533 regulation of protein targeting GO:1903844 regulation of cellular response to transforming growth factor beta stimulus GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus GO:1904018 positive regulation of vasculature development GO:1904177 regulation of adipose tissue development GO:1904179 positive regulation of adipose tissue development GO:1904251 regulation of bile acid metabolic process GO:1904589 regulation of protein import GO:1905268 negative regulation of chromatin organization GO:1905269 positive regulation of chromatin organization GO:1990619 histone H3-K9 deacetylation GO:2000106 regulation of leukocyte apoptotic process GO:2000108 positive regulation of leukocyte apoptotic process GO:2000109 regulation of macrophage apoptotic process GO:2000111 positive regulation of macrophage apoptotic process GO:2000116 regulation of cysteine-type endopeptidase activity GO:2000479 regulation of cAMP-dependent protein kinase activity GO:2000480 negative regulation of cAMP-dependent protein kinase activity GO:2000481 positive regulation of cAMP-dependent protein kinase activity GO:2000618 regulation of histone H4-K16 acetylation GO:2000619 negative regulation of histone H4-K16 acetylation GO:2000654 regulation of cellular response to testosterone stimulus GO:2000655 negative regulation of cellular response to testosterone stimulus GO:2000756 regulation of peptidyl-lysine acetylation GO:2000757 negative regulation of peptidyl-lysine acetylation GO:2000772 regulation of cellular senescence GO:2000773 negative regulation of cellular senescence GO:2000774 positive regulation of cellular senescence GO:2001020 regulation of response to DNA damage stimulus GO:2001021 negative regulation of response to DNA damage stimulus GO:2001022 positive regulation of response to DNA damage stimulus GO:2001056 positive regulation of cysteine-type endopeptidase activity GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway GO:2001242 regulation of intrinsic apoptotic signaling pathway GO:2001243 negative regulation of intrinsic apoptotic signaling pathway GO:2001244 positive regulation of intrinsic apoptotic signaling pathway GO:2001279 regulation of unsaturated fatty acid biosynthetic process
Molecular Function	GO:0001046 core promoter sequence-specific DNA binding GO:0001047 core promoter binding GO:0002039 p53 binding GO:0003714 transcription corepressor activity GO:0004407 histone deacetylase activity GO:0008022 protein C-terminus binding GO:0008134 transcription factor binding GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides GO:0017136 NAD-dependent histone deacetylase activity GO:0019213 deacetylase activity GO:0019215 intermediate filament binding GO:0032129 histone deacetylase activity (H3-K9 specific) GO:0033558 protein deacetylase activity GO:0034979 NAD-dependent protein deacetylase activity GO:0035257 nuclear hormone receptor binding GO:0042393 histone binding GO:0043398 HLH domain binding GO:0043425 bHLH transcription factor binding GO:0046969 NAD-dependent histone deacetylase activity (H3-K9 specific) GO:0048037 cofactor binding GO:0050662 coenzyme binding GO:0051019 mitogen-activated protein kinase binding GO:0051287 NAD binding GO:0051427 hormone receptor binding GO:0070403 NAD+ binding GO:1990254 keratin filament binding
Cellular Component	GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0000791 euchromatin GO:0000792 heterochromatin GO:0005635 nuclear envelope GO:0005637 nuclear inner membrane GO:0005677 chromatin silencing complex GO:0005719 nuclear euchromatin GO:0005720 nuclear heterochromatin GO:0016604 nuclear body GO:0016605 PML body GO:0017053 transcriptional repressor complex GO:0031519 PcG protein complex GO:0031965 nuclear membrane GO:0033553 rDNA heterochromatin GO:0034708 methyltransferase complex GO:0035097 histone methyltransferase complex GO:0035098 ESC/E(Z) complex GO:0044454 nuclear chromosome part GO:0090568 nuclear transcriptional repressor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04068 FoxO signaling pathway hsa04152 AMPK signaling pathway hsa04922 Glucagon signaling pathway
Reactome	R-HSA-3371556: Cellular response to heat stress R-HSA-2262752: Cellular responses to stress R-HSA-400253: Circadian Clock R-HSA-212165: Epigenetic regulation of gene expression R-HSA-74160: Gene Expression R-HSA-5250941: Negative epigenetic regulation of rRNA expression R-HSA-1368082: RORA activates gene expression R-HSA-3371453: Regulation of HSF1-mediated heat shock response R-HSA-427359: SIRT1 negatively regulates rRNA Expression

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04068 FoxO signaling pathway
hsa04152 AMPK signaling pathway
hsa04922 Glucagon signaling pathway

Reactome

R-HSA-3371556: Cellular response to heat stress
R-HSA-2262752: Cellular responses to stress
R-HSA-400253: Circadian Clock
R-HSA-212165: Epigenetic regulation of gene expression
R-HSA-74160: Gene Expression
R-HSA-5250941: Negative epigenetic regulation of rRNA expression
R-HSA-1368082: RORA activates gene expression
R-HSA-3371453: Regulation of HSF1-mediated heat shock response
R-HSA-427359: SIRT1 negatively regulates rRNA Expression

Summary
Symbol	SIRT1
Name	sirtuin 1
Aliases	SIR2L1; sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 1; sirtuin (silent mat ......
Location	10q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Mutation landscape in primary tumor tissue from TCGA > Mutation landscape in cancer cell line from CCLE > All mutations from COSMIC database V81 > Variations from text mining

> The Cancer Genome Atlas (TCGA) [ TOP ]

> Cancer Cell Line Encyclopedia (CCLE) [ TOP ]

> Catalogue of Somatic Mutations in Cancer (COSMIC)

[ TOP ]

COSMIC ID	CDS change	AA change	Mutation Type	Anatomical Site
COSM3415185	c.1628G>T	p.R543I	Substitution - Missense	Large_intestine
COSM3723550	c.620C>T	p.P207L	Substitution - Missense	Upper_aerodigestive_tract
COSM2159033	c.1484G>A	p.G495D	Substitution - Missense	Cervix
COSM684635	c.844C>A	p.R282S	Substitution - Missense	Lung
COSM2159030	c.1178C>G	p.P393R	Substitution - Missense	Central_nervous_system
COSM5782410	c.2070G>A	p.E690E	Substitution - coding silent	Breast
COSM4427531	c.686C>T	p.S229L	Substitution - Missense	Oesophagus
COSM4015204	c.504C>A	p.A168A	Substitution - coding silent	Stomach
COSM4444310	c.1150C>T	p.R384*	Substitution - Nonsense	Large_intestine
COSM4632532	c.408G>A	p.A136A	Substitution - coding silent	Large_intestine
COSM4015205	c.596G>A	p.R199Q	Substitution - Missense	Stomach
COSM4994898	c.1624G>C	p.E542Q	Substitution - Missense	Upper_aerodigestive_tract
COSM1675302	c.1220T>C	p.M407T	Substitution - Missense	Large_intestine
COSM5446258	c.427_428insC	p.R143fs*3	Insertion - Frameshift	Thyroid
COSM5782410	c.2070G>A	p.E690E	Substitution - coding silent	Breast
COSM1265641	c.963C>T	p.F321F	Substitution - coding silent	Stomach
COSM377396	c.1646C>G	p.S549C	Substitution - Missense	Lung
COSM4015207	c.1339C>T	p.P447S	Substitution - Missense	Stomach
COSM465865	c.876T>A	p.D292E	Substitution - Missense	Kidney
COSM5645601	c.1258G>T	p.E420*	Substitution - Nonsense	Oesophagus
COSM1348654	c.1236_1237insT	p.G415fs*2	Insertion - Frameshift	Large_intestine
COSM1731415	c.1447G>T	p.D483Y	Substitution - Missense	Liver
COSM919612	c.1208C>T	p.P403L	Substitution - Missense	Endometrium
COSM465866	c.877C>T	p.P293S	Substitution - Missense	Kidney
COSM1321256	c.477C>T	p.S159S	Substitution - coding silent	Ovary
COSM4015208	c.1546C>T	p.R516*	Substitution - Nonsense	Stomach
COSM3998056	c.994T>C	p.L332L	Substitution - coding silent	Haematopoietic_and_lymphoid_tissue
COSM919614	c.1399G>T	p.E467*	Substitution - Nonsense	Endometrium
COSM277278	c.1547G>A	p.R516Q	Substitution - Missense	Large_intestine
COSM4456587	c.1015C>T	p.L339L	Substitution - coding silent	Skin
COSM4994897	c.568C>A	p.Q190K	Substitution - Missense	Upper_aerodigestive_tract
COSM277278	c.1547G>A	p.R516Q	Substitution - Missense	Large_intestine
COSM4656074	c.306C>T	p.D102D	Substitution - coding silent	Large_intestine
COSM4144791	c.214G>T	p.A72S	Substitution - Missense	Thyroid
COSM919616	c.1558G>T	p.E520*	Substitution - Nonsense	Large_intestine
COSM1675303	c.2059G>A	p.E687K	Substitution - Missense	Large_intestine
COSM1745844	c.476C>T	p.S159F	Substitution - Missense	Urinary_tract
COSM919618	c.2188G>T	p.A730S	Substitution - Missense	Endometrium
COSM4573714	c.1906C>T	p.R636W	Substitution - Missense	Bone
COSM427772	c.1852G>A	p.G618R	Substitution - Missense	Breast
COSM4015206	c.1319G>A	p.G440E	Substitution - Missense	Stomach
COSM215429	c.1945C>T	p.R649C	Substitution - Missense	Endometrium
COSM4726195	c.1289A>C	p.K430T	Substitution - Missense	Large_intestine
COSM267427	c.1850C>T	p.A617V	Substitution - Missense	Large_intestine
COSM5810481	c.907A>T	p.R303*	Substitution - Nonsense	Liver
COSM4165524	c.2135C>A	p.A712D	Substitution - Missense	Kidney
COSM4015210	c.2005A>G	p.S669G	Substitution - Missense	Stomach
COSM3807493	c.1441G>A	p.D481N	Substitution - Missense	Breast
COSM4015209	c.1752T>G	p.T584T	Substitution - coding silent	Stomach
COSM1638616	c.1828delA	p.N611fs*10	Deletion - Frameshift	Stomach
COSM3415184	c.1209G>A	p.P403P	Substitution - coding silent	Large_intestine
COSM919613	c.1260A>G	p.E420E	Substitution - coding silent	Endometrium
COSM139836	c.1891G>A	p.E631K	Substitution - Missense	Skin
COSM1180737	c.760delA	p.I256fs*2	Deletion - Frameshift	Large_intestine
COSM919616	c.1558G>T	p.E520*	Substitution - Nonsense	Large_intestine
COSM1675303	c.2059G>A	p.E687K	Substitution - Missense	Large_intestine
COSM919615	c.1423G>T	p.D475Y	Substitution - Missense	Endometrium
COSM1741914	c.1278G>T	p.M426I	Substitution - Missense	Urinary_tract
COSM5969874	c.1062G>C	p.A354A	Substitution - coding silent	Upper_aerodigestive_tract
COSM919617	c.2094C>T	p.F698F	Substitution - coding silent	Endometrium
COSM5969873	c.1007A>G	p.E336G	Substitution - Missense	Upper_aerodigestive_tract
COSM919611	c.845G>A	p.R282H	Substitution - Missense	Endometrium
COSM4392569	c.2018G>A	p.S673N	Substitution - Missense	Prostate
COSM4651810	c.2227C>T	p.P743S	Substitution - Missense	Large_intestine
COSM3382956	c.682C>A	p.L228I	Substitution - Missense	Pancreas
COSM5784059	c.1822G>A	p.G608R	Substitution - Missense	Breast
COSM358425	c.547+1G>A	p.?	Unknown	Lung
COSM4399350	c.1242T>C	p.F414F	Substitution - coding silent	Skin
COSM1348653	c.1021C>T	p.R341C	Substitution - Missense	Skin
COSM1348653	c.1021C>T	p.R341C	Substitution - Missense	Large_intestine
COSM4981602	c.1379C>T	p.P460L	Substitution - Missense	Oesophagus
COSM1675302	c.1220T>C	p.M407T	Substitution - Missense	Large_intestine
COSM1745844	c.476C>T	p.S159F	Substitution - Missense	Urinary_tract
COSM5953848	c.800C>T	p.S267L	Substitution - Missense	Upper_aerodigestive_tract
COSM5960014	c.40T>C	p.S14P	Substitution - Missense	Thyroid
COSM3439742	c.987C>T	p.F329F	Substitution - coding silent	Skin
COSM4962342	c.1523C>T	p.S508L	Substitution - Missense	Pancreas
COSM2159029	c.1147G>A	p.V383I	Substitution - Missense	Large_intestine
COSM5370972	c.622G>A	p.E208K	Substitution - Missense	Skin
COSM4424971	c.2199G>A	p.V733V	Substitution - coding silent	Oesophagus
COSM3686825	c.341C>A	p.P114Q	Substitution - Missense	Large_intestine
COSM919616	c.1558G>T	p.E520*	Substitution - Nonsense	Endometrium
COSM1180737	c.760delA	p.I256fs*2	Deletion - Frameshift	Large_intestine
COSM5443581	c.1607A>T	p.E536V	Substitution - Missense	Oesophagus
COSM215429	c.1945C>T	p.R649C	Substitution - Missense	Central_nervous_system
COSM5702112	c.828_829GG>TT	p.R276_D277>SY	Complex - compound substitution	Soft_tissue
COSM5003825	c.800C>A	p.S267*	Substitution - Nonsense	Pancreas
COSM919611	c.845G>A	p.R282H	Substitution - Missense	Large_intestine
COSM3375511	c.1095C>A	p.S365S	Substitution - coding silent	Pancreas
COSM3981075	c.1208C>G	p.P403R	Substitution - Missense	Ovary
COSM1348655	c.2024G>A	p.S675N	Substitution - Missense	Large_intestine
COSM5749469	c.1091-2A>G	p.?	Unknown	Genital_tract
COSM3439741	c.942G>A	p.K314K	Substitution - coding silent	Skin
COSM3790886	c.1411C>T	p.H471Y	Substitution - Missense	Urinary_tract
COSM4165523	c.874G>T	p.D292Y	Substitution - Missense	Kidney
COSM323341	c.770T>G	p.I257R	Substitution - Missense	Lung
COSM4833511	c.686C>G	p.S229*	Substitution - Nonsense	Cervix

> Text Mining based Variations

[ TOP ]

PMID	Variation	Cancer	Evidence
23354305	Mutation	Squamous Cell Carcinoma	A global association between genetic variation in the haplotype block where SIRT1 resides and the risk for SCC in miners (P = 0.003) was identified.

Summary
Symbol	SIRT1
Name	sirtuin 1
Aliases	SIR2L1; sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 1; sirtuin (silent mat ......
Location	10q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Post-translational modification (PTM)

> Post-translational modification (PTM)

[ TOP ]

Filter By:

Uniprot ID	Position	Amino Acid	Description	Upstream Enzyme	Affected By Mutation	Amino Acid Sequence Variant
Q96EB6	14	S	Phosphoserine	-	No	None detected
Q96EB6	26	S	Phosphoserine	-	No	None detected
Q96EB6	27	S	Phosphoserine	MAPK8	No	None detected
Q96EB6	47	S	Phosphoserine	MAPK8	No	None detected
Q96EB6	159	S	Phosphoserine	-	No	None detected
Q96EB6	162	S	Phosphoserine	-	No	None detected
Q96EB6	172	S	Phosphoserine	-	No	None detected
Q96EB6	173	S	Phosphoserine	-	No	None detected
Q96EB6	395	C	S-nitrosocysteine	-	No	None detected
Q96EB6	398	C	S-nitrosocysteine	-	No	None detected
Q96EB6	530	T	Phosphothreonine	DYRK1A, DYRK3 and MAPK8	No	None detected
Q96EB6	535	S	Phosphoserine	-	No	None detected
Q96EB6	544	T	Phosphothreonine	-	No	None detected
Q96EB6	545	S	Phosphoserine	-	No	None detected
Q96EB6	659	S	Phosphoserine	CaMK2	No	None detected
Q96EB6	661	S	Phosphoserine	CaMK2	No	None detected
Q96EB6	719	T	Phosphothreonine	-	No	None detected
Q96EB6	747	S	Phosphoserine	-	No	None detected

Summary
Symbol	SIRT1
Name	sirtuin 1
Aliases	SIR2L1; sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 1; sirtuin (silent mat ......
Location	10q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Expression analysis in primary tumor tissue from TCGA > Expression level in cancer cell line from CCLE > Expression level in human normal tissue from HPA > Text mining based expression change

> The Cancer Genome Atlas (TCGA)

[ TOP ]

Differential expression analysis for cancers with more than 10 normal samples

Cancer	Full Name	# N	# T	Median (N)	Median (T)	LogFC	Adj. P	Status
BLCA	Bladder urothelial carcinoma	19	408	5.22	4.22	-1.037	5.12e-10	Under
BRCA	Breast invasive carcinoma	112	1100	5.571	5.156	-0.47	9.49e-15	NS
CESC	Cervical and endocervical cancers	3	306	5.442	4.441	NA	NA	NA
COAD	Colon adenocarcinoma	41	459	4.803	4.554	-0.342	0.00148	NS
ESCA	Esophageal carcinoma	11	185	5.169	4.704	-0.414	0.0402	NS
GBM	Glioblastoma multiforme	5	166	4.392	4.055	NA	NA	NA
HNSC	Head and Neck squamous cell carcinoma	44	522	4.248	3.903	-0.351	0.00042	NS
KIRC	Kidney renal clear cell carcinoma	72	534	4.996	5.086	0.022	0.743	NS
KIRP	Kidney renal papillary cell carcinoma	32	291	4.731	4.359	-0.366	0.000261	NS
LAML	Acute Myeloid Leukemia	0	173	NA	5.474	NA	NA	NA
LGG	Brain Lower Grade Glioma	0	530	NA	5.085	NA	NA	NA
LIHC	Liver hepatocellular carcinoma	50	373	4.499	3.627	-0.85	1.4e-10	Under
LUAD	Lung adenocarcinoma	59	517	5.048	4.841	-0.218	0.00438	NS
LUSC	Lung squamous cell carcinoma	51	501	4.966	4.251	-0.69	4.33e-19	Under
OV	Ovarian serous cystadenocarcinoma	0	307	NA	4.632	NA	NA	NA
PAAD	Pancreatic adenocarcinoma	4	179	4.845	4.485	NA	NA	NA
PCPG	Pheochromocytoma and Paraganglioma	3	184	6.144	4.55	NA	NA	NA
PRAD	Prostate adenocarcinoma	52	498	5.039	5.012	-0.151	0.0683	NS
READ	Rectum adenocarcinoma	10	167	5.21	4.497	-0.809	0.000809	Under
SARC	Sarcoma	2	263	4.491	4.461	NA	NA	NA
SKCM	Skin Cutaneous Melanoma	1	472	4.337	4.137	NA	NA	NA
STAD	Stomach adenocarcinoma	35	415	4.613	4.832	0.096	0.35	NS
TGCT	Testicular Germ Cell Tumors	0	156	NA	5.676	NA	NA	NA
THCA	Thyroid carcinoma	59	509	5.225	4.875	-0.323	4.72e-07	NS
THYM	Thymoma	2	120	5.334	4.763	NA	NA	NA
UCEC	Uterine Corpus Endometrial Carcinoma	35	546	5.436	4.389	-1.064	4.44e-15	Under

> Cancer Cell Line Encyclopedia (CCLE)

[ TOP ]

Tissue	Cell Line	Expression Level (Microarray)
Autonomic ganglia	CHP126	9.6
Autonomic ganglia	CHP212	9
Autonomic ganglia	IMR32	9.7
Autonomic ganglia	KELLY	9.7
Autonomic ganglia	KPNRTBM1	9.8
Autonomic ganglia	KPNSI9S	8.3
Autonomic ganglia	KPNYN	9.4
Autonomic ganglia	MHHNB11	9.8
Autonomic ganglia	NB1	9.3
Autonomic ganglia	NH6	9.4
Autonomic ganglia	SHSY5Y	9.5
Autonomic ganglia	SIMA	9.6
Autonomic ganglia	SKNAS	8.8
Autonomic ganglia	SKNBE2	9.5
Autonomic ganglia	SKNDZ	9.8
Autonomic ganglia	SKNFI	9.1
Autonomic ganglia	SKNSH	9
Biliary tract	HUCCT1	8.2
Biliary tract	HUH28	8.6
Biliary tract	SNU1079	9.3
Biliary tract	SNU1196	8.7
Biliary tract	SNU245	8.3
Biliary tract	SNU308	7.7
Biliary tract	SNU478	9.2
Bone	143B	8.8
Bone	A673	10
Bone	CADOES1	10.2
Bone	CAL78	9.3
Bone	G292CLONEA141B1	8.4
Bone	HOS	8.9
Bone	HS706T	8.5
Bone	HS737T	8.3
Bone	HS819T	8.3
Bone	HS821T	8.6
Bone	HS822T	8.4
Bone	HS863T	8.8
Bone	HS870T	8.5
Bone	HS888T	8.8
Bone	MG63	9.3
Bone	MHHES1	10.6
Bone	OUMS27	8.5
Bone	RDES	9.9
Bone	SJSA1	8.6
Bone	SKES1	9.9
Bone	SKNMC	9.3
Bone	SW1353	8.1
Bone	T173	8.2
Bone	TC71	9.5
Bone	U2OS	9.4
Breast	AU565	8.8
Breast	BT20	8.3
Breast	BT474	9.3
Breast	BT483	8.6
Breast	BT549	10.1
Breast	CAL120	10
Breast	CAL148	9.7
Breast	CAL51	9.3
Breast	CAL851	8.4
Breast	CAMA1	8.8
Breast	DU4475	8.6
Breast	EFM192A	8.3
Breast	EFM19	7.8
Breast	EVSAT	8
Breast	HCC1143	8.6
Breast	HCC1187	8.9
Breast	HCC1395	8.4
Breast	HCC1419	8.5
Breast	HCC1428	9.4
Breast	HCC1500	8.8
Breast	HCC1569	8.3
Breast	HCC1599	9.6
Breast	HCC1806	9.1
Breast	HCC1937	7.6
Breast	HCC1954	7.9
Breast	HCC202	8.3
Breast	HCC2157	9.2
Breast	HCC2218	8.6
Breast	HCC38	8.9
Breast	HCC70	7.1
Breast	HDQP1	8.8
Breast	HMC18	9
Breast	HS274T	8.8
Breast	HS281T	8.9
Breast	HS343T	9.1
Breast	HS578T	8.7
Breast	HS606T	8.5
Breast	HS739T	8.2
Breast	HS742T	8.1
Breast	JIMT1	8.8
Breast	KPL1	9.1
Breast	MCF7	8.8
Breast	MDAMB134VI	9.4
Breast	MDAMB157	8.3
Breast	MDAMB175VII	8.1
Breast	MDAMB231	8.2
Breast	MDAMB361	8.6
Breast	MDAMB415	8.8
Breast	MDAMB436	9
Breast	MDAMB453	8.8
Breast	MDAMB468	9
Breast	SKBR3	9
Breast	T47D	8.7
Breast	UACC812	9.6
Breast	UACC893	8.8
Breast	YMB1	8.7
Breast	ZR751	8.8
Breast	ZR7530	8.7
Central nervous system	1321N1	8.3
Central nervous system	42MGBA	8.8
Central nervous system	8MGBA	8.7
Central nervous system	A172	8.4
Central nervous system	AM38	8.7
Central nervous system	BECKER	8.6
Central nervous system	CAS1	8.6
Central nervous system	CCFSTTG1	8.9
Central nervous system	D283MED	9.3
Central nervous system	D341MED	9.3
Central nervous system	DAOY	8.4
Central nervous system	DBTRG05MG	8
Central nervous system	DKMG	7.7
Central nervous system	GAMG	8.4
Central nervous system	GB1	10.3
Central nervous system	GI1	8.7
Central nervous system	GMS10	8.6
Central nervous system	GOS3	7.5
Central nervous system	H4	8.8
Central nervous system	HS683	8.2
Central nervous system	KALS1	9.1
Central nervous system	KG1C	8.4
Central nervous system	KNS42	7.7
Central nervous system	KNS60	8.9
Central nervous system	KNS81	7.2
Central nervous system	KS1	8.6
Central nervous system	LN18	8.1
Central nervous system	LN229	8.1
Central nervous system	M059K	7.6
Central nervous system	MOGGCCM	7.8
Central nervous system	MOGGUVW	8.1
Central nervous system	NMCG1	8.8
Central nervous system	ONS76	8.2
Central nervous system	SF126	9.1
Central nervous system	SF295	7.9
Central nervous system	SNB19	8.9
Central nervous system	SNU1105	8.8
Central nervous system	SNU201	7.9
Central nervous system	SNU466	8
Central nervous system	SNU489	8.4
Central nervous system	SNU626	8.1
Central nervous system	SNU738	8.2
Central nervous system	SW1088	8.1
Central nervous system	SW1783	8.6
Central nervous system	T98G	7.7
Central nervous system	TM31	8.9
Central nervous system	U118MG	8.8
Central nervous system	U138MG	8.7
Central nervous system	U251MG	8.8
Central nervous system	U87MG	7.8
Central nervous system	YH13	7.8
Central nervous system	YKG1	9.1
Endometrium	AN3CA	9.5
Endometrium	COLO684	10.3
Endometrium	EFE184	9.2
Endometrium	EN	9.3
Endometrium	ESS1	9
Endometrium	HEC108	9.3
Endometrium	HEC151	8
Endometrium	HEC1A	8.1
Endometrium	HEC1B	8.8
Endometrium	HEC251	8.7
Endometrium	HEC265	8.2
Endometrium	HEC50B	8.5
Endometrium	HEC59	9.1
Endometrium	HEC6	9.4
Endometrium	ISHIKAWAHERAKLIO02ER	9.2
Endometrium	JHUEM1	8.8
Endometrium	JHUEM2	9.8
Endometrium	JHUEM3	8.7
Endometrium	KLE	7.7
Endometrium	MFE280	8.5
Endometrium	MFE296	8.6
Endometrium	MFE319	8.3
Endometrium	RL952	8.9
Endometrium	SNGM	8.8
Endometrium	SNU1077	8.8
Endometrium	SNU685	9.7
Endometrium	TEN	9
Haematopoietic and lymphoid	697	9.9
Haematopoietic and lymphoid	A3KAW	8.7
Haematopoietic and lymphoid	A4FUK	8.4
Haematopoietic and lymphoid	ALLSIL	9.3
Haematopoietic and lymphoid	AML193	7.7
Haematopoietic and lymphoid	AMO1	9.7
Haematopoietic and lymphoid	BCP1	9.1
Haematopoietic and lymphoid	BDCM	8.7
Haematopoietic and lymphoid	BL41	10
Haematopoietic and lymphoid	BL70	9.8
Haematopoietic and lymphoid	BV173	9.6
Haematopoietic and lymphoid	CA46	10
Haematopoietic and lymphoid	CI1	8.9
Haematopoietic and lymphoid	CMK115	9.1
Haematopoietic and lymphoid	CMK86	9.5
Haematopoietic and lymphoid	CMK	8.6
Haematopoietic and lymphoid	CMLT1	9.9
Haematopoietic and lymphoid	COLO775	8.9
Haematopoietic and lymphoid	DAUDI	9.4
Haematopoietic and lymphoid	DB	9.2
Haematopoietic and lymphoid	DEL	10.3
Haematopoietic and lymphoid	DND41	8.9
Haematopoietic and lymphoid	DOHH2	9.5
Haematopoietic and lymphoid	EB1	9.5
Haematopoietic and lymphoid	EB2	9.3
Haematopoietic and lymphoid	EHEB	8.2
Haematopoietic and lymphoid	EJM	8.4
Haematopoietic and lymphoid	EM2	8.8
Haematopoietic and lymphoid	EOL1	9.5
Haematopoietic and lymphoid	F36P	8.7
Haematopoietic and lymphoid	GA10	9.9
Haematopoietic and lymphoid	GDM1	8.6
Haematopoietic and lymphoid	GRANTA519	9.8
Haematopoietic and lymphoid	HDLM2	8.9
Haematopoietic and lymphoid	HDMYZ	9.2
Haematopoietic and lymphoid	HEL9217	8.4
Haematopoietic and lymphoid	HEL	8.6
Haematopoietic and lymphoid	HH	8.3
Haematopoietic and lymphoid	HL60	9.2
Haematopoietic and lymphoid	HPBALL	9.4
Haematopoietic and lymphoid	HS604T	8.3
Haematopoietic and lymphoid	HS611T	8.7
Haematopoietic and lymphoid	HS616T	8.2
Haematopoietic and lymphoid	HS751T	8.8
Haematopoietic and lymphoid	HT	10.9
Haematopoietic and lymphoid	HTK	9.1
Haematopoietic and lymphoid	HUNS1	8.7
Haematopoietic and lymphoid	HUT102	8.7
Haematopoietic and lymphoid	HUT78	8
Haematopoietic and lymphoid	JEKO1	9.8
Haematopoietic and lymphoid	JK1	9.4
Haematopoietic and lymphoid	JM1	10
Haematopoietic and lymphoid	JURKAT	9.5
Haematopoietic and lymphoid	JURLMK1	9.5
Haematopoietic and lymphoid	JVM2	8.7
Haematopoietic and lymphoid	JVM3	9.5
Haematopoietic and lymphoid	K562	9.2
Haematopoietic and lymphoid	KARPAS299	8.7
Haematopoietic and lymphoid	KARPAS422	9.5
Haematopoietic and lymphoid	KARPAS620	9
Haematopoietic and lymphoid	KASUMI1	9.7
Haematopoietic and lymphoid	KASUMI2	9.2
Haematopoietic and lymphoid	KASUMI6	9.2
Haematopoietic and lymphoid	KCL22	9.5
Haematopoietic and lymphoid	KE37	9.5
Haematopoietic and lymphoid	KE97	8.6
Haematopoietic and lymphoid	KG1	8.6
Haematopoietic and lymphoid	KHM1B	8.3
Haematopoietic and lymphoid	KIJK	8.7
Haematopoietic and lymphoid	KMH2	10.4
Haematopoietic and lymphoid	KMM1	8.3
Haematopoietic and lymphoid	KMS11	8.6
Haematopoietic and lymphoid	KMS12BM	8.4
Haematopoietic and lymphoid	KMS18	9
Haematopoietic and lymphoid	KMS20	9.3
Haematopoietic and lymphoid	KMS21BM	8.4
Haematopoietic and lymphoid	KMS26	9.3
Haematopoietic and lymphoid	KMS27	8.9
Haematopoietic and lymphoid	KMS28BM	9.4
Haematopoietic and lymphoid	KMS34	8.8
Haematopoietic and lymphoid	KO52	9.1
Haematopoietic and lymphoid	KOPN8	8.7
Haematopoietic and lymphoid	KU812	8.9
Haematopoietic and lymphoid	KYO1	8.8
Haematopoietic and lymphoid	L1236	8.2
Haematopoietic and lymphoid	L363	10.6
Haematopoietic and lymphoid	L428	9.1
Haematopoietic and lymphoid	L540	9
Haematopoietic and lymphoid	LAMA84	10
Haematopoietic and lymphoid	LOUCY	9.3
Haematopoietic and lymphoid	LP1	9.7
Haematopoietic and lymphoid	M07E	9.7
Haematopoietic and lymphoid	MC116	9.1
Haematopoietic and lymphoid	ME1	8.3
Haematopoietic and lymphoid	MEC1	9.6
Haematopoietic and lymphoid	MEC2	8.4
Haematopoietic and lymphoid	MEG01	7.6
Haematopoietic and lymphoid	MHHCALL2	9.5
Haematopoietic and lymphoid	MHHCALL3	9.1
Haematopoietic and lymphoid	MHHCALL4	9.4
Haematopoietic and lymphoid	MINO	9.7
Haematopoietic and lymphoid	MJ	8.8
Haematopoietic and lymphoid	MM1S	9
Haematopoietic and lymphoid	MOLM13	8.9
Haematopoietic and lymphoid	MOLM16	9.8
Haematopoietic and lymphoid	MOLM6	9.5
Haematopoietic and lymphoid	MOLP2	8.9
Haematopoietic and lymphoid	MOLP8	8.8
Haematopoietic and lymphoid	MOLT13	9.3
Haematopoietic and lymphoid	MOLT16	9
Haematopoietic and lymphoid	MOLT4	8.5
Haematopoietic and lymphoid	MONOMAC1	9.9
Haematopoietic and lymphoid	MONOMAC6	9.9
Haematopoietic and lymphoid	MOTN1	8.8
Haematopoietic and lymphoid	MUTZ5	9.2
Haematopoietic and lymphoid	MV411	9.1
Haematopoietic and lymphoid	NALM19	9.5
Haematopoietic and lymphoid	NALM1	9.2
Haematopoietic and lymphoid	NALM6	9.9
Haematopoietic and lymphoid	NAMALWA	9.9
Haematopoietic and lymphoid	NB4	9.5
Haematopoietic and lymphoid	NCIH929	7.4
Haematopoietic and lymphoid	NCO2	9.6
Haematopoietic and lymphoid	NOMO1	9
Haematopoietic and lymphoid	NUDHL1	8.8
Haematopoietic and lymphoid	NUDUL1	10
Haematopoietic and lymphoid	OCIAML2	9.1
Haematopoietic and lymphoid	OCIAML3	9.3
Haematopoietic and lymphoid	OCIAML5	8.9
Haematopoietic and lymphoid	OCILY10	9.4
Haematopoietic and lymphoid	OCILY19	10
Haematopoietic and lymphoid	OCILY3	8.7
Haematopoietic and lymphoid	OCIM1	9.8
Haematopoietic and lymphoid	OPM2	9.1
Haematopoietic and lymphoid	P12ICHIKAWA	8.8
Haematopoietic and lymphoid	P31FUJ	8.6
Haematopoietic and lymphoid	P3HR1	9.4
Haematopoietic and lymphoid	PCM6	7.5
Haematopoietic and lymphoid	PEER	9.1
Haematopoietic and lymphoid	PF382	9.4
Haematopoietic and lymphoid	PFEIFFER	9.7
Haematopoietic and lymphoid	PL21	8.8
Haematopoietic and lymphoid	RAJI	9.1
Haematopoietic and lymphoid	RCHACV	9.8
Haematopoietic and lymphoid	REC1	9.6
Haematopoietic and lymphoid	REH	9.2
Haematopoietic and lymphoid	RI1	9.6
Haematopoietic and lymphoid	RL	9
Haematopoietic and lymphoid	RPMI8226	8
Haematopoietic and lymphoid	RPMI8402	9.4
Haematopoietic and lymphoid	RS411	9
Haematopoietic and lymphoid	SEM	9.5
Haematopoietic and lymphoid	SET2	8.8
Haematopoietic and lymphoid	SIGM5	8.6
Haematopoietic and lymphoid	SKM1	8.6
Haematopoietic and lymphoid	SKMM2	9.3
Haematopoietic and lymphoid	SR786	10.1
Haematopoietic and lymphoid	ST486	9.1
Haematopoietic and lymphoid	SUDHL10	9.2
Haematopoietic and lymphoid	SUDHL1	9.4
Haematopoietic and lymphoid	SUDHL4	8.7
Haematopoietic and lymphoid	SUDHL5	10
Haematopoietic and lymphoid	SUDHL6	9.4
Haematopoietic and lymphoid	SUDHL8	9.2
Haematopoietic and lymphoid	SUPB15	8.8
Haematopoietic and lymphoid	SUPHD1	8.9
Haematopoietic and lymphoid	SUPM2	9.4
Haematopoietic and lymphoid	SUPT11	8.7
Haematopoietic and lymphoid	SUPT1	8.6
Haematopoietic and lymphoid	TALL1	9.7
Haematopoietic and lymphoid	TF1	9.6
Haematopoietic and lymphoid	THP1	7.8
Haematopoietic and lymphoid	TO175T	8.5
Haematopoietic and lymphoid	TOLEDO	9.5
Haematopoietic and lymphoid	U266B1	8.6
Haematopoietic and lymphoid	U937	8.3
Haematopoietic and lymphoid	UT7	8.7
Haematopoietic and lymphoid	WSUDLCL2	9.3
Kidney	769P	8.2
Kidney	786O	8.2
Kidney	A498	8.2
Kidney	A704	8.9
Kidney	ACHN	8.7
Kidney	BFTC909	9.1
Kidney	CAKI1	8.3
Kidney	CAKI2	8.2
Kidney	CAL54	8.1
Kidney	KMRC1	9.1
Kidney	KMRC20	8.7
Kidney	KMRC2	9
Kidney	KMRC3	8.9
Kidney	OSRC2	9.1
Kidney	RCC10RGB	8.5
Kidney	SNU1272	9.3
Kidney	SNU349	9.3
Kidney	TUHR10TKB	8.5
Kidney	TUHR14TKB	8.7
Kidney	TUHR4TKB	8.6
Kidney	VMRCRCW	8.6
Kidney	VMRCRCZ	8.6
Large intestine	C2BBE1	9.6
Large intestine	CCK81	9.4
Large intestine	CL11	9
Large intestine	CL14	8.5
Large intestine	CL34	9.4
Large intestine	CL40	8.2
Large intestine	COLO205	8
Large intestine	COLO320	8.8
Large intestine	COLO678	9.3
Large intestine	CW2	8.8
Large intestine	DLD1	8.9
Large intestine	GP2D	9.4
Large intestine	HCC56	8.6
Large intestine	HCT116	9
Large intestine	HCT15	9.1
Large intestine	HS675T	8.2
Large intestine	HS698T	8.8
Large intestine	HT115	8.3
Large intestine	HT29	8.3
Large intestine	HT55	8.7
Large intestine	KM12	9.7
Large intestine	LOVO	8.8
Large intestine	LS1034	8.6
Large intestine	LS123	9.4
Large intestine	LS180	9
Large intestine	LS411N	9.7
Large intestine	LS513	8.3
Large intestine	MDST8	8.5
Large intestine	NCIH508	8.5
Large intestine	NCIH716	8.8
Large intestine	NCIH747	8.3
Large intestine	OUMS23	8.2
Large intestine	RCM1	8
Large intestine	RKO	8.3
Large intestine	SKCO1	9
Large intestine	SNU1040	9.1
Large intestine	SNU1197	8.3
Large intestine	SNU175	9.4
Large intestine	SNU283	8.7
Large intestine	SNU407	9.3
Large intestine	SNU503	7.9
Large intestine	SNU61	9
Large intestine	SNU81	10.3
Large intestine	SNUC1	7.7
Large intestine	SNUC2A	9
Large intestine	SNUC4	9
Large intestine	SNUC5	9.3
Large intestine	SW1116	8.5
Large intestine	SW1417	8.7
Large intestine	SW1463	7.9
Large intestine	SW403	8.4
Large intestine	SW480	8
Large intestine	SW48	9.8
Large intestine	SW620	8.9
Large intestine	SW837	9.4
Large intestine	SW948	7.8
Large intestine	T84	8.2
Liver	ALEXANDERCELLS	7.8
Liver	C3A	8.3
Liver	HEP3B217	8.2
Liver	HEPG2	8
Liver	HLE	9
Liver	HLF	9.1
Liver	HUH1	8.5
Liver	HUH6	9.7
Liver	HUH7	8.5
Liver	JHH1	8.4
Liver	JHH2	8.5
Liver	JHH4	8.8
Liver	JHH5	7.6
Liver	JHH6	9.9
Liver	JHH7	8.5
Liver	LI7	9
Liver	PLCPRF5	8
Liver	SKHEP1	9.4
Liver	SNU182	8.8
Liver	SNU387	8
Liver	SNU398	9.6
Liver	SNU423	9.1
Liver	SNU449	8.6
Liver	SNU475	8.6
Liver	SNU761	8.7
Liver	SNU878	8.4
Liver	SNU886	9.3
Lung	A549	9.3
Lung	ABC1	8.7
Lung	BEN	9
Lung	CAL12T	8.2
Lung	CALU1	7.8
Lung	CALU3	9.1
Lung	CALU6	8.3
Lung	CHAGOK1	9.1
Lung	COLO668	9
Lung	COLO699	9
Lung	CORL105	9
Lung	CORL23	8.6
Lung	CORL24	9.9
Lung	CORL279	9.2
Lung	CORL311	9.4
Lung	CORL47	8.7
Lung	CORL51	9.5
Lung	CORL88	8.8
Lung	CORL95	9.3
Lung	CPCN	9.1
Lung	DMS114	9.9
Lung	DMS153	9.2
Lung	DMS273	8.9
Lung	DMS454	9.3
Lung	DMS53	8.4
Lung	DMS79	8.6
Lung	DV90	8
Lung	EBC1	8.5
Lung	EPLC272H	8.6
Lung	HARA	8.7
Lung	HCC1171	8.4
Lung	HCC1195	7.4
Lung	HCC15	8.9
Lung	HCC2279	9
Lung	HCC2935	8.1
Lung	HCC33	9.3
Lung	HCC366	9.7
Lung	HCC4006	9
Lung	HCC44	8.7
Lung	HCC78	8.8
Lung	HCC827	8.3
Lung	HCC95	8.5
Lung	HLC1	9.1
Lung	HLFA	8.2
Lung	HS229T	8.7
Lung	HS618T	8.3
Lung	IALM	8.5
Lung	KNS62	8.5
Lung	LC1F	8.7
Lung	LC1SQSF	8.8
Lung	LCLC103H	8.9
Lung	LCLC97TM1	8.7
Lung	LK2	8.4
Lung	LOUNH91	8.2
Lung	LU65	9.5
Lung	LU99	9.3
Lung	LUDLU1	8.2
Lung	LXF289	9.5
Lung	MORCPR	8.7
Lung	NCIH1048	9.6
Lung	NCIH1092	9.3
Lung	NCIH1105	9.1
Lung	NCIH1155	9.7
Lung	NCIH1184	9.2
Lung	NCIH1299	8.7
Lung	NCIH1339	8.5
Lung	NCIH1341	7.7
Lung	NCIH1355	9
Lung	NCIH1373	8.1
Lung	NCIH1385	8.8
Lung	NCIH1395	7.6
Lung	NCIH1435	8.5
Lung	NCIH1436	9.6
Lung	NCIH1437	8.7
Lung	NCIH146	9.4
Lung	NCIH1563	8.4
Lung	NCIH1568	8.4
Lung	NCIH1573	8.6
Lung	NCIH1581	9.8
Lung	NCIH1618	9.4
Lung	NCIH1623	8.1
Lung	NCIH1648	8.4
Lung	NCIH1650	8.7
Lung	NCIH1651	7.7
Lung	NCIH1666	8.5
Lung	NCIH1693	8
Lung	NCIH1694	9
Lung	NCIH1703	9.6
Lung	NCIH1734	8.4
Lung	NCIH1755	9.1
Lung	NCIH1781	8.6
Lung	NCIH1792	8.1
Lung	NCIH1793	8.6
Lung	NCIH1836	9.3
Lung	NCIH1838	8.5
Lung	NCIH1869	8.7
Lung	NCIH1876	9.7
Lung	NCIH1915	9.6
Lung	NCIH1930	8.7
Lung	NCIH1944	8.2
Lung	NCIH1963	8.6
Lung	NCIH196	8.3
Lung	NCIH1975	8.6
Lung	NCIH2009	8.6
Lung	NCIH2023	8.8
Lung	NCIH2029	8.4
Lung	NCIH2030	9.1
Lung	NCIH2066	8.8
Lung	NCIH2081	8.6
Lung	NCIH2085	7.7
Lung	NCIH2087	7.8
Lung	NCIH209	9.1
Lung	NCIH2106	9.1
Lung	NCIH2110	9.2
Lung	NCIH211	8.2
Lung	NCIH2122	8
Lung	NCIH2126	8.5
Lung	NCIH2141	9.2
Lung	NCIH2170	8.1
Lung	NCIH2171	8
Lung	NCIH2172	9.4
Lung	NCIH2196	8.6
Lung	NCIH2227	9.5
Lung	NCIH2228	8.1
Lung	NCIH226	7.9
Lung	NCIH2286	9.2
Lung	NCIH2291	8.1
Lung	NCIH2342	7.9
Lung	NCIH2347	7.9
Lung	NCIH23	9
Lung	NCIH2405	9.4
Lung	NCIH2444	7.6
Lung	NCIH292	8.6
Lung	NCIH322	8.4
Lung	NCIH3255	8.3
Lung	NCIH358	7.6
Lung	NCIH441	7.9
Lung	NCIH446	8.8
Lung	NCIH460	8.7
Lung	NCIH510	9.3
Lung	NCIH520	9.4
Lung	NCIH522	9.8
Lung	NCIH524	8.5
Lung	NCIH526	8.6
Lung	NCIH596	8.7
Lung	NCIH647	8.7
Lung	NCIH650	8.3
Lung	NCIH661	9.1
Lung	NCIH69	8.5
Lung	NCIH727	8.3
Lung	NCIH810	8.3
Lung	NCIH82	9.2
Lung	NCIH838	8.9
Lung	NCIH841	9.2
Lung	NCIH854	8.6
Lung	NCIH889	8.6
Lung	PC14	8.2
Lung	RERFLCAD1	9.3
Lung	RERFLCAD2	8.3
Lung	RERFLCAI	8.6
Lung	RERFLCKJ	8
Lung	RERFLCMS	9
Lung	RERFLCSQ1	8.7
Lung	SBC5	9.2
Lung	SCLC21H	9.1
Lung	SHP77	8.2
Lung	SKLU1	8
Lung	SKMES1	7.2
Lung	SQ1	8.4
Lung	SW1271	8.7
Lung	SW1573	9.1
Lung	SW900	8.5
Lung	VMRCLCD	9.5
Lung	VMRCLCP	8.9
Oesophagus	COLO680N	8.2
Oesophagus	ECGI10	8.8
Oesophagus	KYSE140	8.9
Oesophagus	KYSE150	8.6
Oesophagus	KYSE180	8.4
Oesophagus	KYSE270	8.6
Oesophagus	KYSE30	8.2
Oesophagus	KYSE410	8.2
Oesophagus	KYSE450	8.3
Oesophagus	KYSE510	8.2
Oesophagus	KYSE520	8.9
Oesophagus	KYSE70	9.2
Oesophagus	OE19	7.2
Oesophagus	OE33	9.6
Oesophagus	TE10	8.5
Oesophagus	TE11	8.2
Oesophagus	TE14	8.5
Oesophagus	TE15	7.3
Oesophagus	TE1	9.3
Oesophagus	TE4	8.9
Oesophagus	TE5	8.6
Oesophagus	TE6	8.1
Oesophagus	TE8	8.7
Oesophagus	TE9	8
Oesophagus	TT	8.4
Ovary	59M	9.5
Ovary	A2780	10
Ovary	CAOV3	9
Ovary	CAOV4	8.4
Ovary	COLO704	9.9
Ovary	COV318	7.6
Ovary	COV362	8.8
Ovary	COV434	9.2
Ovary	COV504	8.3
Ovary	COV644	8.6
Ovary	EFO21	9.1
Ovary	EFO27	7.8
Ovary	ES2	8.7
Ovary	FUOV1	9.2
Ovary	HEYA8	8.4
Ovary	HS571T	7.6
Ovary	IGROV1	9
Ovary	JHOC5	9.1
Ovary	JHOM1	8.5
Ovary	JHOM2B	9.4
Ovary	JHOS2	8.2
Ovary	JHOS4	9.1
Ovary	KURAMOCHI	8.7
Ovary	MCAS	9.2
Ovary	NIHOVCAR3	9.2
Ovary	OAW28	8.6
Ovary	OAW42	8.8
Ovary	OC314	8.1
Ovary	OC316	8.4
Ovary	ONCODG1	9.8
Ovary	OV56	9
Ovary	OV7	9
Ovary	OV90	8.6
Ovary	OVCAR4	8.8
Ovary	OVCAR8	8.9
Ovary	OVISE	8.4
Ovary	OVK18	9.7
Ovary	OVKATE	8.9
Ovary	OVMANA	10
Ovary	OVSAHO	9.1
Ovary	OVTOKO	8.1
Ovary	RMGI	9.2
Ovary	RMUGS	7.1
Ovary	SKOV3	9
Ovary	SNU119	8.2
Ovary	SNU840	8.2
Ovary	SNU8	8.3
Ovary	TOV112D	9.1
Ovary	TOV21G	8.8
Ovary	TYKNU	8.8
Pancreas	ASPC1	8.7
Pancreas	BXPC3	7.7
Pancreas	CAPAN1	8.7
Pancreas	CAPAN2	8.3
Pancreas	CFPAC1	8.7
Pancreas	DANG	7.9
Pancreas	HPAC	8.8
Pancreas	HPAFII	8.3
Pancreas	HS766T	8.3
Pancreas	HUPT3	6.8
Pancreas	HUPT4	8.5
Pancreas	KCIMOH1	8.9
Pancreas	KLM1	9.3
Pancreas	KP2	8.6
Pancreas	KP3	9.4
Pancreas	KP4	9.8
Pancreas	L33	8.1
Pancreas	MIAPACA2	8.7
Pancreas	PANC0203	8.9
Pancreas	PANC0213	8.4
Pancreas	PANC0327	8.2
Pancreas	PANC0403	8.4
Pancreas	PANC0504	7.4
Pancreas	PANC0813	8.1
Pancreas	PANC1005	8.6
Pancreas	PANC1	9.9
Pancreas	PATU8902	9
Pancreas	PATU8988S	8.8
Pancreas	PATU8988T	10
Pancreas	PK1	8.1
Pancreas	PK45H	9.6
Pancreas	PK59	8.7
Pancreas	PL45	9.2
Pancreas	PSN1	8.1
Pancreas	QGP1	9.1
Pancreas	SNU213	8.5
Pancreas	SNU324	9
Pancreas	SNU410	9.1
Pancreas	SU8686	8.5
Pancreas	SUIT2	8.9
Pancreas	SW1990	8.3
Pancreas	T3M4	7.7
Pancreas	TCCPAN2	8.2
Pancreas	YAPC	9.1
Pleura	ACCMESO1	8.4
Pleura	DM3	8.1
Pleura	ISTMES1	8.3
Pleura	ISTMES2	7.9
Pleura	JL1	8.1
Pleura	MPP89	8.1
Pleura	MSTO211H	8.4
Pleura	NCIH2052	8.5
Pleura	NCIH2452	8.3
Pleura	NCIH28	7.9
Prostate	22RV1	9.1
Prostate	DU145	9.3
Prostate	LNCAPCLONEFGC	8.5
Prostate	MDAPCA2B	8.5
Prostate	NCIH660	9.6
Prostate	PC3	9.2
Prostate	VCAP	8.7
Salivary gland	A253	8.3
Salivary gland	YD15	8.7
Skin	A101D	7.7
Skin	A2058	9.1
Skin	A375	8.3
Skin	C32	8.3
Skin	CHL1	8.2
Skin	CJM	9.4
Skin	COLO679	8
Skin	COLO741	8.1
Skin	COLO783	8
Skin	COLO792	8.6
Skin	COLO800	7.8
Skin	COLO818	8
Skin	COLO829	7.4
Skin	COLO849	8
Skin	G361	7.2
Skin	GRM	9
Skin	HMCB	8.7
Skin	HS294T	7.2
Skin	HS600T	8.2
Skin	HS688AT	8.6
Skin	HS695T	7.7
Skin	HS839T	8.9
Skin	HS852T	9.2
Skin	HS895T	8.1
Skin	HS934T	9
Skin	HS936T	7.7
Skin	HS939T	7.3
Skin	HS940T	8.1
Skin	HS944T	8.3
Skin	HT144	7.1
Skin	IGR1	7.9
Skin	IGR37	7.9
Skin	IGR39	8.8
Skin	IPC298	7.8
Skin	K029AX	7.5
Skin	LOXIMVI	8.8
Skin	MALME3M	7.5
Skin	MDAMB435S	8.3
Skin	MELHO	7.5
Skin	MELJUSO	8.3
Skin	MEWO	9
Skin	RPMI7951	8.5
Skin	RVH421	7.6
Skin	SH4	8.5
Skin	SKMEL1	7.5
Skin	SKMEL24	7.4
Skin	SKMEL28	7.8
Skin	SKMEL2	7.4
Skin	SKMEL30	8.8
Skin	SKMEL31	7.5
Skin	SKMEL3	6.7
Skin	SKMEL5	7.8
Skin	UACC257	8
Skin	UACC62	7.2
Skin	WM115	7.3
Skin	WM1799	8.5
Skin	WM2664	8.2
Skin	WM793	8.3
Skin	WM88	8.2
Skin	WM983B	7.9
Small intestine	HUTU80	9.5
Soft tissue	A204	8.7
Soft tissue	G401	8.9
Soft tissue	G402	8.4
Soft tissue	GCT	8.4
Soft tissue	HS729	9
Soft tissue	HT1080	8
Soft tissue	KYM1	9.1
Soft tissue	MESSA	8.4
Soft tissue	RD	9.1
Soft tissue	RH30	9.1
Soft tissue	RH41	9.5
Soft tissue	RKN	7.7
Soft tissue	S117	9.4
Soft tissue	SJRH30	8.2
Soft tissue	SKLMS1	8.1
Soft tissue	SKUT1	9.7
Soft tissue	TE125T	8.9
Soft tissue	TE159T	8.4
Soft tissue	TE441T	9.5
Soft tissue	TE617T	9.7
Stomach	2313287	9.4
Stomach	AGS	9
Stomach	AZ521	9.4
Stomach	ECC10	9.7
Stomach	ECC12	9.2
Stomach	FU97	7.8
Stomach	GCIY	8.7
Stomach	GSS	9.5
Stomach	GSU	8.8
Stomach	HGC27	8.8
Stomach	HS746T	9.1
Stomach	HUG1N	8.7
Stomach	IM95	7.9
Stomach	KATOIII	8
Stomach	KE39	8.3
Stomach	LMSU	9.1
Stomach	MKN1	8.3
Stomach	MKN45	9.1
Stomach	MKN74	10
Stomach	MKN7	8.2
Stomach	NCCSTCK140	8.6
Stomach	NCIN87	8.6
Stomach	NUGC2	6.8
Stomach	NUGC3	8.4
Stomach	NUGC4	7.6
Stomach	OCUM1	8.2
Stomach	RERFGC1B	8.4
Stomach	SH10TC	8.6
Stomach	SNU16	8.8
Stomach	SNU1	8.7
Stomach	SNU216	8.6
Stomach	SNU520	9.2
Stomach	SNU5	8.6
Stomach	SNU601	9.4
Stomach	SNU620	10.4
Stomach	SNU668	10.3
Stomach	SNU719	9.7
Stomach	TGBC11TKB	9.4
Thyroid	8305C	8.1
Thyroid	8505C	8.5
Thyroid	BCPAP	9.2
Thyroid	BHT101	8.8
Thyroid	CAL62	9.4
Thyroid	CGTHW1	8.4
Thyroid	FTC133	9.4
Thyroid	FTC238	8.3
Thyroid	ML1	9.2
Thyroid	SW579	8.1
Thyroid	TT2609C02	9.6
Thyroid	TT	9
Upper aerodigestive tract	BHY	7.7
Upper aerodigestive tract	BICR16	8
Upper aerodigestive tract	BICR18	7.7
Upper aerodigestive tract	BICR22	8.5
Upper aerodigestive tract	BICR31	8.1
Upper aerodigestive tract	BICR56	8.5
Upper aerodigestive tract	BICR6	8.9
Upper aerodigestive tract	CAL27	8
Upper aerodigestive tract	CAL33	8.5
Upper aerodigestive tract	DETROIT562	8.3
Upper aerodigestive tract	FADU	8.4
Upper aerodigestive tract	HS840T	8
Upper aerodigestive tract	HSC2	7.8
Upper aerodigestive tract	HSC3	8.4
Upper aerodigestive tract	HSC4	8.3
Upper aerodigestive tract	PECAPJ15	7.5
Upper aerodigestive tract	PECAPJ34CLONEC12	8
Upper aerodigestive tract	PECAPJ41CLONED2	8.6
Upper aerodigestive tract	PECAPJ49	8.2
Upper aerodigestive tract	SCC15	8
Upper aerodigestive tract	SCC25	8.3
Upper aerodigestive tract	SCC4	7.8
Upper aerodigestive tract	SCC9	8.2
Upper aerodigestive tract	SNU1076	7.5
Upper aerodigestive tract	SNU1214	7.8
Upper aerodigestive tract	SNU46	9
Upper aerodigestive tract	SNU899	8
Upper aerodigestive tract	YD10B	8.8
Upper aerodigestive tract	YD38	8.5
Upper aerodigestive tract	YD8	8.6
Urinary tract	5637	7.6
Urinary tract	639V	9
Urinary tract	647V	9.1
Urinary tract	BC3C	8.5
Urinary tract	BFTC905	8.9
Urinary tract	CAL29	8.7
Urinary tract	HS172T	9
Urinary tract	HT1197	7.5
Urinary tract	HT1376	7.7
Urinary tract	J82	7.9
Urinary tract	JMSU1	10.1
Urinary tract	KMBC2	8.5
Urinary tract	KU1919	7.5
Urinary tract	RT11284	8.5
Urinary tract	RT112	7.9
Urinary tract	RT4	7.9
Urinary tract	SCABER	8.2
Urinary tract	SW1710	9.2
Urinary tract	SW780	7.7
Urinary tract	T24	8.2
Urinary tract	TCCSUP	10.3
Urinary tract	UMUC1	8.5
Urinary tract	UMUC3	9.3
Urinary tract	VMCUB1	8.6

> The Human Protein Atlas (HPA)

[ TOP ]

Tissue	Expression Level (TPM)
Adipose tissue	18.4
Adrenal gland	40.8
Appendix	15.3
Bone marrow	12.4
Breast	21.7
Cerebral cortex	14.7
Cervix, uterine	26.2
Colon	11.1
Duodenum	9.5
Endometrium	30.4
Epididymis	14.3
Esophagus	12.2
Fallopian tube	19.5
Gallbladder	22.5
Heart muscle	7.6
Kidney	14.2
Liver	9
Lung	18.8
Lymph node	20.6
Ovary	30.8
Pancreas	2.5
Parathyroid gland	24.4
Placenta	18
Prostate	22.6
Rectum	13.5
Salivary gland	4.3
Seminal vesicle	15.5
Skeletal muscle	3.7
Skin	11.4
Small intestine	11.1
Smooth muscle	20.2
Spleen	20
Stomach	9.6
Testis	48.8
Thyroid gland	24.7
Tonsil	14.4
Urinary bladder	17.3

> Text Mining based Expression

[ TOP ]

PMID	Expression	Cancer	Evidence
28070138	Overexpression	Gastric Carcinoma	High Beclin-1 and SIRT1 expression alone and their combined high expression predicted shorter overall survival and relapse-free survival.
28061480	Overexpression	Gastric Carcinoma	Our results revealed upregulated expression of SIRT1 in all stages of gastric cancer compared with noncancerous gastric mucosa, suggesting that high SIRT1 levels are likely involved in establishing gastric neoplasticity.
27793057	Overexpression	Thyroid Carcinoma	Compared to normal thyroid tissue, thyroid tumors had lower expression of HIC1 and higher SIRT1 expression.
27793039	Overexpression	Osteosarcoma	The SIRT1 protein was significantly upregulated in most primary osteosarcoma tumours, compared with normal tissues, and the SIRT1 expression level may be coupled with metastatic risk in patients with osteosarcoma.
27768839	Overexpression	Non-Small Cell Lung Cancer	MRNA level of SIRT1 was upregulated in NSCLC tissues as compared to normal tissues (3.18±0.77 vs. 1.27±0.62; P=.001).
26862948	Overexpression	Ovarian Carcinoma	However, elevated SIRT1 expression was a significant predictor of shorter survival in univariate (P=0.038) and multivariate (P=0.037) survival analyses, regardless of the tumor stage. Results of the present study suggest a positive role for SIRT1 in the development of OvCa and its potential as a novel therapeutic target.
27748572	Overexpression	Hepatocellular Carcinoma	SIRT1 was overexpressed in human HCC tissues and was negatively related to miR-204-5p levels.
27720890	Overexpression	Squamous Cell Carcinoma	All 24 cases of invasive and microinvasive SCC showed SIRT1 over-expression with 25% (6/24) showing cytoplasmic staining only, 4.2% (1/24) showing nuclear staining only, and 70.8% (17/24) showing both nuclear and cytoplasmic staining.
27312708	Overexpression	Hepatocellular Carcinoma	Our data show that SIRT1 is highly expressed in liver CSCs and decreases during differentiation. In addition, high levels of SIRT1 predict a decreased probability of survival in patients with HCC.
27277416	Overexpression	Breast Carcinoma; Triple-Negative Breast Carcinoma	Immunohistochemical expressions of FOXM1, FOXO3a, SIRT1 and SIRT6 were evaluated in tissue microarray blocks containing 688 consecutive breast cancer samples.
27145368	Overexpression	Colorectal Carcinoma	Moreover, Kaplan-Meier curves showed that CRC patients with high expression level of miR-199b had a longer median survival. Functional assays results indicated that the restoration of miR-199b considerably reduced cell invasion and migration in vitro and in vivo, and increased the sensitivity to 5-FU and oxaliplatin. Further dual-luciferase reporter gene assays revealed that SIRT1 was the direct target of miR-199b in CRC. The expression of miR-199b was inversely correlated with SIRT1 in CRC specimens.
27080717	Underexpression	Breast Carcinoma	Particularly, expressions of SIRT1 and SIRT4 were found to be significantly down-regulated in breast cancer tissues and SKBR3 breast cancer cells.
27072976	Overexpression	Gastric Carcinoma	A total of 1650 patients in 7 studies were included according to the inclusion criteria and exclusion criteria. The high expression of Sirt1 was found in 58.4% cases by immunohistochemistry.
26999517	Overexpression; SNP	Breast Carcinoma	Breast cancer patients exhibited elevated serum SIRT1 levels which varied among different tumor grades. SIRT1 rs3758391 and rs12778366 TT genotypes were more frequent, exhibited higher SIRT1 levels than CC and CT genotypes and were associated with histologic grade and lymph node status.
26902145	Underexpression	Breast Carcinoma	Importantly, this mechanism is manifested in breast cancer patient samples and TCGA database, which showed that low SIRT1 gene expression in tumor tissues compared with normal adjacent tissues predicts poor prognosis in patients with breast cancer.
26862948	Overexpression	Endometrial Adenocarcinoma; Mucinous Adenocarcinoma; Clear Cell Adenocarcinoma	The expression of SIRT1 was higher in endometrioid, mucinous, and clear-cell carcinomas than in the inclusion cysts of normal ovaries, but not in serous carcinoma (P=0.038).
26824501	Overexpression	Hepatocellular Carcinoma	SIRT1 levels were elevated in human HCC compared to adjacent normal liver tissue, and its expression correlated positively with p-p38 levels.
26794150	Overexpression	Chronic Lymphocytic Leukemia	We showed that both primary CLL cells and JVM-3 and MEC-2 cell lines overexpress high levels of functional SIRT1 and SIRT2.
26763348	Overexpression	Colorectal Carcinoma	Simultaneously, SIRT1 overexpression predicted a poor OS in CRC patients, and SIRT1 is a candidate negative prognostic biomarker for CRC patients.
26701732	Underexpression	Endometrial Carcinoma	Compared to NNE, ECs showed SIRT7 (p < 0.001) mRNA overexpression, whereas SIRT1 (p < 0.001), SIRT2 (p < 0.001), SIRT4 (p < 0.001) and SIRT5 (p < 0.001) were underexpressed.
26662958	Overexpression	Esophageal Squamous Cell Carcinoma	Basal expression levels of SIRT1 protein in ESCC tumor tissues and cell lines were higher than those in the control groups.
26655844	Overexpression	Pancreatic Carcinoma	We show that SIRT1 is highly expressed in pancreatic cancer cells and that the STACs SRT1720, SRT1460, and SRT3025 inhibited cell growth and survival of pancreatic cancer cells.
26363315	Overexpression	Colorectal Carcinoma	Clinical analysis revealed a significant association between high SIRT1 expression and poor outcome in CRC patients.
26318035	Overexpression	Lung Carcinoma	SIRT1 was overexpressed in the lung of B[a]P-exposed mice and in human lung cancer biopsies.
26091232	Overexpression	Adult T-Cell Leukemia/Lymphoma	We previously reported that ATL patients had significantly higher SIRT1 protein levels than healthy controls.
25995644	Overexpression	Lung Adenocarcinoma	A high expression level of SIRT1 was observed in 74.7% (56/75) of patients with lung adenocarcinoma and 6.7% (5/75) of NCTs (P<0.001).
25915617	Overexpression	non-Small Cell Lung Carcinoma	High SIRT1 and SIRT2 protein levels were found in NSCLC cell lines compared with non-tumor lung epithelial cells.
25884180	Overexpression	Acute Lymphoblastic Leukemia	In the present study, we initially found that the level of SIRT1, a class III histone deacetylase, was higher in primary ALL cells from patients than in peripheral blood mononuclear cells from healthy individuals.
25785061	Overexpression	Colorectal Carcinoma	The expressions of SIRT1 and Phospho-SIRT1 were higher in colorectal cancer tissues than normal tissues.
25785036	Overexpression	Breast Carcinoma	The pooled analyses showed a significant correlation between SIRT1 expression and poor disease-free survival (DFS) (HR = 3.07, 95% CI: 1.92-4.91, Z = 4.69, P < 0.001) and overall survival (OS) (HR = 3.94, 95% CI: 2.19-7.10, Z = 4.57, P < 0.001).
25652855	Overexpression	Hepatocellular Carcinoma	The expression of miR-204 in HCC tissues was significantly lower than that in tumor-adjacent normal tissues. miR-204 could inhibit HCC cell proliferation and induce apoptosis by down-regulating the expressions of Bcl-2 and Sirt1.
25522783	Overexpression	Hepatocellular Carcinoma	SIRT1 expression was significantly overexpressed in the tumor tissues and HCC cell lines.
25503141	Underexpression	Head and Neck Squamous Cell Carcinoma	The expression profiles of the 7 SIRT genes of PB leukocytes from 34 patients with HNSCC before and after surgery and 31 healthy individuals were investigated. In the cancer group, the expression level of SIRT1 was down-regulated (p<0.05); in contrast, SIRT6 and SIRT7 were significantly up-regulated (p<0.001).
25503141	Overexpression	Colorectal Carcinoma	We found that many CRC specimens had strong SIRT1 expression, which had an obvious correlation with poor prognosis of CRC patients.
25424420	Underexpression	Oral Squamous Cell Carcinoma	We found that compared with normal human oral keratinocytes (HOKs), SIRT1 was underexpressed in OSCC cells, and also in oral cancer tissues obtained from 14 of 21 OSCC patients compared with expression in their matched normal tissues.
25420528	Overexpression	Breast Carcinoma	SIRT1, N1IC, and Snail were all found to be highly expressed and an inverse correlation between SIRT1 and N1IC in breast cancer tissue.
25341037	Overexpression	Synovial Sarcoma	We show that SIRT1 is overexpressed in synovial sarcoma biopsies and cell lines in comparison with normal mesenchymal cells.
25281719	Overexpression	Ewing Sarcoma	Using immunohistochemistry to analyze primary tissue specimens, we found that high SIRT1 expression was associated with Ewing sarcoma metastasis and poor prognosis.
25270091	Overexpression	Endometrial Carcinoma	Expression levels of SIRT1 in EC were found to be significantly higher than in normal endometrium.
25172416	Overexpression	Pancreatic Carcinoma	Consistently, miR-217 was obviously down-regulated in CP, PC and TGF-β1 treated PC cells, while negatively correlated to its direct target SIRT1. Moreover, either ectopic expression of miR-217 or inhibition of SIRT1 remarkably induced mesenchymal to epithelial transition (MET) in TGF-β1 treated PC cells.
25146318	Overexpression	Gastric Carcinoma	We found that SIRT1 high expression closely correlates with progression and prognosis in gastric cancer patients.
25139823	Overexpression	Breast Carcinoma	Immunohistochemical staining for LSD1, HDAC2 and SIRT1 was performed on tissue microarrays of tumor and corresponding normal formalin-fixed paraffin-embedded tissues from breast cancer patients. Expression of LSD1 and SIRT1, but not of HDAC2, was significantly increased in tumor tissues compared to their normal counterparts (both p < 0.001).
24959282	Overexpression	Lung Adenocarcinoma	Immunohistochemical staining was performed to investigate Sirt1 expression in cancer cells in 125 consecutive resected cases of primary lung adenocarcinoma. Sirt1 expression was found to be increased in 26 (20.8%) of the 125 cases, which correlated significantly with five clinicopathological factors: Ki67 index, hypoxia-inducible factor 1 (HIF1) molecule expression, tumor-node-metastasis (TNM) classification, pulmonary vein invasion and lymphatic duct invasion.
24927438	Overexpression	Acute Myeloid Leukemia	SIRT1 is overexpressed in some of pediatric AML patients, and the overexpression of SIRT1 is associated with poor prognosis.
24855208	Overexpression	Acute Myeloid Leukemia	We show that SIRT1 protein, but not RNA levels, is overexpressed in AML samples harboring activating mutations in signaling pathways.
24816737	Overexpression	Colorectal Adenocarcinoma	There was significant difference in SIRT1 overexpression between adenocarcinomas and normal mucosal tissues (P < 0.01, χ(2) test).
24751483	Overexpression	Melanoma	We have found that SIRT1 is overexpressed in clinical human melanoma tissues and human melanoma cell lines (Sk-Mel-2, WM35, G361, A375, and Hs294T) compared to normal skin and normal melanocytes, respectively.
24343700	Overexpression	Cutaneous T-Cell Non-Hodgkin Lymphoma	Our results indicate that SIRT1 is strongly expressed in CTCL.
24338587	Overexpression	Hepatocellular Carcinoma	Finally, we found that human hepatocellular carcinoma (HCC) samples have increased presence of SIRT1, which correlated with the absence of FXR, suggesting its oncogenic potential.
24228097	Overexpression	non-Small Cell Lung Carcinoma	Furthermore, SIRT1 is found to be highly expressed in brain metastasis tissues of NSCLC, compared to the NSCLC tissues, suggesting that SIRT1 may play roles in brain metastasis of NSCL
24223900	Overexpression	Non-Small Cell Lung Carcinoma	This study was to explore the association between the SIRT1 expression and the clinical characteristics, the responsiveness to chemotherapy and prognosis in Non-small cell lung cancer (NSCLC). We found that the SIRT1 expressions were significantly associated with the tumor stage, tumor size and differentiation status. Patients with high expression of SIRT1 had significantly shorter OS and DFS than those with low expression.
24127549	Underexpression	Prostate Carcinoma	We found that H2AFZ and SIRT1 were up- and downregulated, respectively, at transcript level in primary prostate cancer and high-grade prostatic intraepithelial neoplasia compared to normal prostatic tissues.
24107295	Underexpression	Gastric Carcinoma	SIRT1 was present in all normal gastric mucosa specimens; however, it was only present in a portion of the matched gastric cancer tumor specimens. In SIRT1-positive tumors, both mRNA and protein levels were downregulated as compared with the corresponding nonneoplastic tissue.
24035280	Overexpression	Gastroesophageal Junction Cancer	Tissue microarray technique and immunohistochemical stains were applied to evaluate the SIRT1, p300/CBP, E-cadherin, and MLH1 expression in 176 GEJ cancer tissues and 32 normal GEJ region tissues. The results showed that the over-expression of SIRT1 was associated with a higher number of metastasis lymph nodes, more advanced staging, and shorter mean survival time.
24009628	Overexpression	Colorectal Carcinoma	Immunohistochemical expressions of SIRT1, DBC1, β-catenin, surviving, and p53 were evaluated using 2 mm tumor cores from 349 colorectal cancer patients for tissue microarray. Overexpression of SIRT1, DBC1, survivin, and p53 was seen in 235 (67%), 183 (52%), 193 (55%), and 190 (54%) patients, respectively.
23843607	Underexpression	Ovarian Carcinoma	Importantly, analysis of human ovarian tumor specimens indicated that PIASy expression was positively, whereas SIRT1 expression was inversely, correlated with cancer aggressiveness. In summary, our work has identified a new pathway that links downregulation of SIRT1 to hypoxia-induced EMT in ovarian cancer cells and, as such, sheds light on the development of novel anti-tumor therapeutics.
23768087	Overexpression	Gastric Carcinoma	We verified that miR-204 levels were down-regulated and significantly associated with the up-regulation of SIRT1 mRNA levels in gastric cancer specimens.
23728341	Overexpression	Hepatocellular Carcinoma	Aberrant SIRT1 overexpression was demonstrated in a subset of human HCCs.
23542177	Overexpression	Hepatocellular Carcinoma	In our experiments, we observed that the expression of SIRT1 is significantly upregulated in the tumor samples of the hepatocarcinoma patients, and SIRT1 mRNA level positively correlates with connective tissue growth factor (CTGF) mRNA level.
23475622	Underexpression	Head and Neck Squamous Cell Carcinoma	Our results demonstrated that the expression levels of SIRT1, SIRT2, SIRT3, SIRT5, SIRT6, and SIRT7 were significantly downregulated in cancerous tissues compared with noncancerous tissues (all p<0.01).
23453030	Underexpression	Head and Neck Squamous Cell Carcinoma	SIRT1 expression was assessed by immunohistochemistry (IHC) conducted using samples from 437 consecutive HNSCC patients. IHC revealed 79.6% staining of SIRT1 in HNSCC, while almost all normal tissues showed positive staining.
23340254	Overexpression	Invasive Ductal Carcinoma	Finally, we demonstrate by immunohistochemistry that SIRT1 is significantly up-regulated in invasive ductal carcinoma relative to normal tissue adjacent to tumor, further suggesting a role of SIRT1 in breast cancer.
23339189	Overexpression	Hepatocellular Carcinoma	Our data show that compared with normal liver or surrounding tumor tissue, SIRT1 is strongly overexpressed in human hepatocellular carcinoma (HCC).
23248098	Overexpression	Prostate Carcinoma	Androgen-independent prostate cancer cell lines (C42B, PC3, and DU145) express higher levels of SIRT1 than androgen-responsive (LNCaP) and nontumorigenic prostate cells (RWPE-1).
23038275	Overexpression	Prostate Carcinoma	Furthermore, we determined that SIRT1 inhibition reduced prostate cancer cell invasion and SIRT1 is highly expressed in advanced prostate cancer tissues.
22986747	Overexpression	Non-Small Cell Lung Carcinoma	Using these profiles and four independent gene expression datasets, we found that SIRT1 activity is significantly upregulated in cytologically normal bronchial airway epithelial cells from active smokers compared with nonsmokers. In contrast, this activity is strikingly downregulated in non-small cell lung cancer.
22986535	Overexpression	Thyroid Gland Carcinoma	Similarly, SIRT1 is overexpressed in human thyroid cancers and it is positively correlated with c-MYC protein levels.
22554968	Underexpression	Colorectal Adenoma;Colorectal Adenocarcinoma; Colorectal Carcinoma	SIRT1 protein expression, determined by immunohistochemistry, was investigated in human normal colonic mucosa, adenoma, adenocarcinoma and metastatic tissue samples. All normal colonic mucosa showed SIRT1 expression with no exception, and 42 (80.8%) of 52 adenomatous polyps were positive for SIRT1. However, only 208 (41.9%) of 497 colorectal adenocarcinomas were positive. Moreover, 45 (35.7%) of 126 metastatic tissues were positive. Collectively, the SIRT1 expression was gradually decreased during carcinogenesis and tumour progression.
22340598	Overexpression	Chronic Myelogenous Leukemia	We show that the NAD(+)-dependent deacetylase SIRT1 is overexpressed in human CML LSC.
22322739	Overexpression	Adult T-Cell Leukemia/Lymphoma	SIRT1 expression in ATL patients was significantly higher than that in healthy controls, especially in the acute type.
22149272	Underexpression	Colorectal Carcinoma	In CRC, SIRT1 mean expression level was decreased.
22146883	Overexpression	Hepatocellular Carcinoma	SIRT1 was overexpressed in 95 of 172 HCCs (55%).
21865267	Overexpression	Gastric Carcinoma	SIRT1 expression in gastric cardiac carcinoma was significantly higher than that in normal gastric cardiac tissues and was associated with lymphatic metastasis, TNM stage, survival rate and mean survival time.
21677689	Overexpression	Pancreatic Carcinoma	SIRT1 was overexpressed in pancreatic cancer tissues at both the mRNA and protein levels, with increased SIRT1 positivity associated with tumors from patients over 60 years old, tumors larger than 4 cm, higher TNM (extent of tumor (T), the extent of spread to lymph nodes (N), and presence of distant metastasis (M)) stage or the presence of lymph node or hepatic metastases.
21596753	Overexpression	Breast Carcinoma	Finally, we observed SIRT1 overexpression in association with decreased miR-200a in breast cancer patient samples.
21567102	Overexpression	Hepatocellular Carcinoma	Overexpression of SIRT1 and p53 was observed in 56% (50 of 90) and in 30% (27 of 90) of the HCCs, respectively.
21555002	Overexpression	Chronic Myeloid Leukemia	SIRT1 was also found to be up regulated in cell lines and in chronic myeloid leukemia patient samples where EVI1 was detected.
21527554	Overexpression	Hepatocellular Carcinoma	We showed that although SIRT1 was expressed at very low levels in normal livers, it was overexpressed in HCC cell lines and in a subset of HCC.
21149730	Underexpression	Skin Neoplasm	Finally, we show that SIRT1 levels are significantly reduced in human skin tumors from Caucasian patients, a population at highest risk.
20956937	Overexpression	Prostate Carcinoma	In this study, we show that NAMPT is prominently overexpressed in human prostate cancer cells along with SIRT1.
20412117	Overexpression	Breast Carcinoma	The aim of the present study was to simultaneously evaluate the expression levels of SIRT1 and DBC1 in the normal and tumor breast tissues from 28 breast cancer patients and to determine correlations with clinicopathological variables. SIRT1 and DBC1 expression was higher in tumor tissues than in matched normal tissues at the protein level, but not at the transcriptional level.

Summary
Symbol	SIRT1
Name	sirtuin 1
Aliases	SIR2L1; sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 1; sirtuin (silent mat ......
Location	10q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Somatic copy number alteration in primary tomur tissue

> The Cancer Genome Atlas (TCGA)

[ TOP ]

Correlation between expression and SCNA as well as percentage of patients in different status.

Cancer	Full Name	# Sample	R	P	% Loss	% Neutral	% Gain	Status
BLCA	Bladder urothelial carcinoma	404	0.307	2.72e-10	34.4	55.2	10.4	Loss
BRCA	Breast invasive carcinoma	1075	0.404	1.52e-43	21.5	65.5	13	Neutral
CESC	Cervical and endocervical cancers	292	0.405	5.96e-13	25	69.2	5.8	Neutral
COAD	Colon adenocarcinoma	449	0.328	9.36e-13	18.9	75.5	5.6	Neutral
ESCA	Esophageal carcinoma	183	0.521	4.23e-14	27.3	53	19.7	Neutral
GBM	Glioblastoma multiforme	147	0.562	1.38e-13	90.5	9.5	0	Loss
HNSC	Head and Neck squamous cell carcinoma	514	0.285	4.32e-11	23.7	67.7	8.6	Neutral
KIRC	Kidney renal clear cell carcinoma	525	0.282	4.79e-11	16.8	81	2.3	Neutral
KIRP	Kidney renal papillary cell carcinoma	288	0.2	0.000651	6.2	91.3	2.4	Neutral
LAML	Acute Myeloid Leukemia	166	0.103	0.188	0.6	97.6	1.8	Neutral
LGG	Brain Lower Grade Glioma	513	0.647	4.16e-62	19.7	79.5	0.8	Neutral
LIHC	Liver hepatocellular carcinoma	364	0.2	0.000119	21.7	67.6	10.7	Neutral
LUAD	Lung adenocarcinoma	512	0.454	2.33e-27	25.6	58.4	16	Neutral
LUSC	Lung squamous cell carcinoma	498	0.532	8.18e-38	44.4	43.6	12	Loss
OV	Ovarian serous cystadenocarcinoma	300	0.644	1.54e-36	27.3	50.3	22.3	Neutral
PAAD	Pancreatic adenocarcinoma	177	0.127	0.0915	15.8	77.4	6.8	Neutral
PCPG	Pheochromocytoma and Paraganglioma	162	0.03	0.702	0.6	93.2	6.2	Neutral
PRAD	Prostate adenocarcinoma	491	0.258	6.65e-09	11	84.7	4.3	Neutral
READ	Rectum adenocarcinoma	164	0.283	0.000238	22.6	72.6	4.9	Neutral
SARC	Sarcoma	255	0.36	3.33e-09	54.5	41.6	3.9	Loss
SKCM	Skin Cutaneous Melanoma	367	0.39	8.2e-15	60.5	38.4	1.1	Loss
STAD	Stomach adenocarcinoma	413	0.519	7.92e-30	17.2	64.2	18.6	Neutral
TGCT	Testicular Germ Cell Tumors	150	0.081	0.327	51.3	44	4.7	Loss
THCA	Thyroid carcinoma	497	0.215	1.33e-06	2	97.6	0.4	Neutral
THYM	Thymoma	119	0.061	0.508	1.7	96.6	1.7	Neutral
UCEC	Uterine Corpus Endometrial Carcinoma	537	0.311	1.76e-13	10.1	68.3	21.6	Neutral

Summary
Symbol	SIRT1
Name	sirtuin 1
Aliases	SIR2L1; sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 1; sirtuin (silent mat ......
Location	10q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Methylation level in the promoter region of CR

> Methylation level in the promoter region of CR

[ TOP ]

Correlation between expression and methylation as well as differential methylation analysis.

Cancer	Full Name	R	P	# N	# T	Delta beta (T vs N)	P value (T vs N)	Status
BLCA	Bladder urothelial carcinoma	-0.053	0.274	17	408	-0.001	0.178	NS/NA
BRCA	Breast invasive carcinoma	-0.276	1.58e-16	83	785	0.003	0.496	NS/NA
CESC	Cervical and endocervical cancers	-0.228	5.34e-05	3	306	NA	NA	NS/NA
COAD	Colon adenocarcinoma	-0.157	0.00523	19	297	0.002	0.0078	NS/NA
ESCA	Esophageal carcinoma	-0.296	3.09e-05	9	185	NA	NA	NS/NA
GBM	Glioblastoma multiforme	-0.47	9.53e-05	1	64	NA	NA	NS/NA
HNSC	Head and Neck squamous cell carcinoma	-0.218	3.16e-07	20	522	0.005	8.44e-13	NS/NA
KIRC	Kidney renal clear cell carcinoma	-0.105	0.053	24	319	0.002	4.16e-07	NS/NA
KIRP	Kidney renal papillary cell carcinoma	-0.255	8.54e-06	23	275	0.001	0.225	NS/NA
LAML	Acute Myeloid Leukemia	-0.095	0.217	0	170	NA	NA	NS/NA
LGG	Brain Lower Grade Glioma	-0.244	1.48e-08	0	530	NA	NA	NS/NA
LIHC	Liver hepatocellular carcinoma	-0.199	4.74e-05	41	373	0.001	0.00854	NS/NA
LUAD	Lung adenocarcinoma	-0.157	0.000565	21	456	0.012	6.08e-06	NS/NA
LUSC	Lung squamous cell carcinoma	-0.257	4.38e-07	8	370	NA	NA	NS/NA
OV	Ovarian serous cystadenocarcinoma	-0.667	0.0589	0	9	NA	NA	NS/NA
PAAD	Pancreatic adenocarcinoma	-0.155	0.0364	4	179	NA	NA	NS/NA
PCPG	Pheochromocytoma and Paraganglioma	-0.096	0.19	3	184	NA	NA	NS/NA
PRAD	Prostate adenocarcinoma	-0.191	9.65e-06	35	498	0.004	3.3e-12	NS/NA
READ	Rectum adenocarcinoma	-0.167	0.0943	2	99	NA	NA	NS/NA
SARC	Sarcoma	-0.276	5.82e-06	0	263	NA	NA	NS/NA
SKCM	Skin Cutaneous Melanoma	-0.348	8.33e-15	1	471	NA	NA	NS/NA
STAD	Stomach adenocarcinoma	-0.327	1.37e-10	0	372	NA	NA	NS/NA
TGCT	Testicular Germ Cell Tumors	-0.305	0.000116	0	156	NA	NA	NS/NA
THCA	Thyroid carcinoma	-0.138	0.00108	50	509	0	0.71	NS/NA
THYM	Thymoma	-0.164	0.0711	2	120	NA	NA	NS/NA
UCEC	Uterine Corpus Endometrial Carcinoma	-0.173	0.000174	34	431	0	0.92	NS/NA

Summary
Symbol	SIRT1
Name	sirtuin 1
Aliases	SIR2L1; sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 1; sirtuin (silent mat ......
Location	10q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Primary tumor tissue from TCGA > Normal tumor tissue from HPA

>The Cancer Genome Atlas (TCGA) [ TOP ]
There is no record.

> The Human Protein Atlas (HPA)

[ TOP ]

Tissue	Level	Level Name
Adrenal gland	3	High
Appendix	1	Low
Bone marrow	2	Medium
Breast	0	Not detected
Bronchus	0	Not detected
Caudate	1	Low
Cerebellum	1	Low
Cerebral cortex	0	Not detected
Cervix, uterine	1	Low
Colon	1	Low
Duodenum	1	Low
Endometrium	1	Low
Epididymis	0	Not detected
Esophagus	0	Not detected
Fallopian tube	1	Low
Gallbladder	1	Low
Heart muscle	1	Low
Hippocampus	1	Low
Kidney	1	Low
Liver	0	Not detected
Lung	0	Not detected
Lymph node	3	High
Nasopharynx	1	Low
Oral mucosa	0	Not detected
Ovary	1	Low
Pancreas	1	Low
Parathyroid gland	0	Not detected
Placenta	2	Medium
Prostate	1	Low
Rectum	0	Not detected
Salivary gland	0	Not detected
Seminal vesicle	1	Low
Skeletal muscle	1	Low
Skin	1	Low
Small intestine	1	Low
Smooth muscle	1	Low
Soft tissue	0	Not detected
Spleen	1	Low
Stomach	1	Low
Testis	3	High
Thyroid gland	0	Not detected
Tonsil	2	Medium
Urinary bladder	1	Low
Vagina	0	Not detected

Summary
Symbol	SIRT1
Name	sirtuin 1
Aliases	SIR2L1; sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 1; sirtuin (silent mat ......
Location	10q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Association between expresson and subtype > Overall survival analysis based on expression > Association between expresson and stage > Association between expresson and grade

> Subtype

[ TOP ]

Association between expresson and subtype.

Cancer	Full Name	# Patients	P Value (Kruskal-Wallis)	Association	Source
BLCA	Bladder urothelial carcinoma	128	0.906	NS	24476821
BRCA	Breast invasive carcinoma	521	1.78e-10	Significant	23000897
COAD	Colon adenocarcinoma	149	0.607	NS	22810696
GBM	Glioblastoma multiforme	157	1.23e-05	Significant	26824661
HNSC	Head and Neck squamous cell carcinoma	279	0.00945	Significant	25631445
KIRP	Kidney renal papillary cell carcinoma	161	0.178	NS	26536169
LGG	Brain Lower Grade Glioma	513	4.52e-37	Significant	26824661
LUAD	Lung adenocarcinoma	230	2.09e-05	Significant	25079552
LUSC	Lung squamous cell carcinoma	178	0.000531	Significant	22960745
OV	Ovarian serous cystadenocarcinoma	287	0.036	Significant	21720365
PRAD	Prostate adenocarcinoma	333	0.000381	Significant	26544944
READ	Rectum adenocarcinoma	67	0.228	NS	22810696
SKCM	Skin Cutaneous Melanoma	315	8.86e-07	Significant	26091043
STAD	Stomach adenocarcinoma	277	0.486	NS	25079317
THCA	Thyroid carcinoma	391	2.51e-07	Significant	25417114
UCEC	Uterine Corpus Endometrial Carcinoma	232	0.308	NS	23636398

> Overall survival

[ TOP ]

Overall survival analysis based on expression.

Cancer	Full Name	# Patients	Hazard Ratio	P Value (Log Rank Test)	Association
BLCA	Bladder urothelial carcinoma	405	0.888	0.576	NS
BRCA	Breast invasive carcinoma	1079	0.914	0.688	NS
CESC	Cervical and endocervical cancers	291	1.473	0.239	NS
COAD	Colon adenocarcinoma	439	0.736	0.297	NS
ESCA	Esophageal carcinoma	184	1.703	0.136	NS
GBM	Glioblastoma multiforme	158	0.612	0.0465	Longer
HNSC	Head and Neck squamous cell carcinoma	518	0.752	0.15	NS
KIRC	Kidney renal clear cell carcinoma	531	0.385	9.8e-06	Longer
KIRP	Kidney renal papillary cell carcinoma	287	2.761	0.0386	Shorter
LAML	Acute Myeloid Leukemia	149	0.731	0.287	NS
LGG	Brain Lower Grade Glioma	511	0.254	2.27e-09	Longer
LIHC	Liver hepatocellular carcinoma	365	0.605	0.0499	Longer
LUAD	Lung adenocarcinoma	502	0.793	0.253	NS
LUSC	Lung squamous cell carcinoma	494	0.944	0.774	NS
OV	Ovarian serous cystadenocarcinoma	303	0.885	0.569	NS
PAAD	Pancreatic adenocarcinoma	177	0.996	0.986	NS
PCPG	Pheochromocytoma and Paraganglioma	179	2.534	0.413	NS
PRAD	Prostate adenocarcinoma	497	2.057	0.426	NS
READ	Rectum adenocarcinoma	159	0.677	0.578	NS
SARC	Sarcoma	259	1.321	0.327	NS
SKCM	Skin Cutaneous Melanoma	459	0.641	0.0243	Longer
STAD	Stomach adenocarcinoma	388	1.049	0.835	NS
TGCT	Testicular Germ Cell Tumors	134	1	1	NS
THCA	Thyroid carcinoma	500	0.704	0.6	NS
THYM	Thymoma	119	3.642	0.217	NS
UCEC	Uterine Corpus Endometrial Carcinoma	543	1.328	0.33	NS

> Stage

[ TOP ]

Association between expresson and stage.

Cancer	Full Name	# Patients	R Value (Spearman)	P Value (Spearman)	Association
BLCA	Bladder urothelial carcinoma	406	-0.072	0.147	NS
BRCA	Breast invasive carcinoma	1071	-0.046	0.134	NS
CESC	Cervical and endocervical cancers	167	0.131	0.0922	NS
COAD	Colon adenocarcinoma	445	-0.095	0.045	Lower
ESCA	Esophageal carcinoma	162	0.084	0.289	NS
HNSC	Head and Neck squamous cell carcinoma	448	-0.025	0.601	NS
KIRC	Kidney renal clear cell carcinoma	531	-0.204	2.04e-06	Lower
KIRP	Kidney renal papillary cell carcinoma	260	0.13	0.0364	Higher
LIHC	Liver hepatocellular carcinoma	347	0.053	0.321	NS
LUAD	Lung adenocarcinoma	507	0.015	0.74	NS
LUSC	Lung squamous cell carcinoma	497	0.062	0.168	NS
OV	Ovarian serous cystadenocarcinoma	302	-0.096	0.0955	NS
PAAD	Pancreatic adenocarcinoma	176	0.047	0.534	NS
READ	Rectum adenocarcinoma	156	0.101	0.208	NS
SKCM	Skin Cutaneous Melanoma	410	-0.079	0.112	NS
STAD	Stomach adenocarcinoma	392	0.085	0.0943	NS
TGCT	Testicular Germ Cell Tumors	81	0.067	0.55	NS
THCA	Thyroid carcinoma	499	-0.024	0.596	NS
UCEC	Uterine Corpus Endometrial Carcinoma	501	0.021	0.635	NS

> Grade

[ TOP ]

Association between expresson and grade.

Cancer	Full Name	# Patients	R Value (Spearman)	P Value (Spearman)	Association
CESC	Cervical and endocervical cancers	272	-0.098	0.108	NS
HNSC	Head and Neck squamous cell carcinoma	498	0.144	0.00132	Higher
KIRC	Kidney renal clear cell carcinoma	525	-0.256	2.8e-09	Lower
LGG	Brain Lower Grade Glioma	514	-0.154	0.000459	Lower
LIHC	Liver hepatocellular carcinoma	366	-0.103	0.0497	Lower
OV	Ovarian serous cystadenocarcinoma	296	-0.069	0.234	NS
PAAD	Pancreatic adenocarcinoma	176	-0.137	0.069	NS
STAD	Stomach adenocarcinoma	406	0.101	0.0412	Higher
UCEC	Uterine Corpus Endometrial Carcinoma	534	0.097	0.0247	Higher

Summary
Symbol	SIRT1
Name	sirtuin 1
Aliases	SIR2L1; sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 1; sirtuin (silent mat ......
Location	10q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Targets inferred by reverse engineering method > Targets identified by ChIP-seq data

> Targets inferred by reverse engineering method [ TOP ]

> Targets identified by ChIP-seq data [ TOP ]

Summary
Symbol	SIRT1
Name	sirtuin 1
Aliases	SIR2L1; sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 1; sirtuin (silent mat ......
Location	10q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Drugs from DrugBank database

> Drugs from DrugBank database

[ TOP ]

DrugBank ID	Name	Type	All Targets
DB05073	SRT501	Small Molecule Drug

Summary
Symbol	SIRT1
Name	sirtuin 1
Aliases	SIR2L1; sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 1; sirtuin (silent mat ......
Location	10q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Protein-Protein Interaction Network > miRNA Regulatory Relationship > Interactions from Text Mining

> Protein-Protein Interaction Network [ TOP ]

> miRNA Regulatory Relationship [ TOP ]

> Interactions from Text Mining

[ TOP ]

PMID	Cancer	Hierarchy	Gene	Relation to CR	Evidence
28070138	Gastric Carcinoma	partner	Beclin-1	correlation	High Beclin-1 and SIRT1 expression alone and their combined high expression predicted shorter overall survival and relapse-free survival.
28061480	Gastric Carcinoma	partner	STAT3	correlation	Moreover, co-ordinated high expression of SIRT1 and STAT3 predicted poor overall survival for advanced gastric cancer patients.
27748572	Hepatocellular Carcinoma	upstream	miR-204-5p	Negative regulation	SIRT1 was a potential oncogene in cancer, which was identified as a direct target of miR-204-5p. SIRT1 was overexpressed in human HCC tissues and was negatively related to miR-204-5p levels.
27312708	Hepatocellular Carcinoma	upstream	Insulin growth factor	positive regulation	Furthermore, we demonstrated that insulin growth factor signaling plays an important role in maintaining SIRT1 expression through increased SIRT1 protein stability.
27312708	Hepatocellular Carcinoma	downstream	SOX2	Regulation	Mechanistically, SIRT1 regulates transcription of the SOX2 gene by way of chromatin-based epigenetic changes, which are dependent on DNA methylation
27277416	Breast Carcinoma; Triple-Negative Breast Carcinoma	partner	FOXM1	Positive correlation	High expression of FOXM1 was significantly correlated with high SIRT1 and SIRT6 expression, higher histologic grade and triple-negative breast cancer (TNBC).
27145368	Colorectal Carcinoma	partner	miR-199b	Negative correlation	In the present study, by comparing the miRNA expression profiles of CRC tissues and corresponding hepatic metastasis tissues, we established the downregulation of miR-199b in CRC metastasis tissues. The decrease in miR-199b expression was significantly correlated to late TNM stage and distant metastasis. Moreover, Kaplan-Meier curves showed that CRC patients with high expression level of miR-199b had a longer median survival. Functional assays results indicated that the restoration of miR-199b considerably reduced cell invasion and migration in vitro and in vivo, and increased the sensitivity to 5-FU and oxaliplatin. Further dual-luciferase reporter gene assays revealed that SIRT1 was the direct target of miR-199b in CRC. The expression of miR-199b was inversely correlated with SIRT1 in CRC specimens.
26902145	Breast Carcinoma	upstream	BRCA1	Positive regulation	We reveal that overexpression of BRCA1 significantly inhibited expression of AR through activation of SIRT1 in breast cancer cells.
26902145	Breast Carcinoma	downstream	AR	Positive regulation	We reveal that overexpression of BRCA1 significantly inhibited expression of AR through activation of SIRT1 in breast cancer cells.
26824501	Hepatocellular Carcinoma	downstream	p38; MKK3; YAP	Positive regulation	SIRT1 levels were elevated in human HCC compared to adjacent normal liver tissue, and its expression correlated positively with p-p38 levels. Additionally, SIRT1-activated p38 increased liver cancer malignancy. SIRT1 increased phosphorylation and nuclear accumulation of p38, possibly by increasing MKK3 expression. SIRT1 also induced YAP expression, which in turn increased MKK3 transcription.
26318035	Lung Carcinoma	downstream	TNF-α; β-catenin; E-cadherin	Positive regulation; positive regulation; negative regulation	SIRT1 up-regulated TNF-α and β-catenin and down-regulated the membrane fraction of E-cadherin.
25995644	Lung Adenocarcinoma	partner	VEGF	Positive correlation	Moreover, the SIRT1 and VEGF expression statuses were significantly positively correlated (r=0.238, P=0.039), while SIRT1 and Survivin expression status were not significantly correlated (r=0.220, P=0.058).
25785061	Colorectal Carcinoma	partner	Phospho-SIRT1; Ki67	Positive correlation; correlation	SIRT1 and Phospho-SIRT1 were highly correlated in cancer tissues and normal tissues. Phospho-SIRT1 expression in cancer tissues was associated with Ki67.
25652855	Hepatocellular Carcinoma	upstream	miR-204	Negative regulation	The expression of miR-204 in HCC tissues was significantly lower than that in tumor-adjacent normal tissues. miR-204 could inhibit HCC cell proliferation and induce apoptosis by down-regulating the expressions of Bcl-2 and Sirt1.
25503141	Colorectal Carcinoma	downstream	Oct4; Nanog; Cripto; Tert; Lin28	Positive regulation	Further study demonstrated that the expressions of several stemness-associated genes, including Oct4, Nanog, Cripto, Tert and Lin28, were reduced by SIRT1 knockdown in CRC cells.
25424420	Oral Squamous Cell Carcinoma	downstream	E-cadherin; Smad4; TGF-β-induced signaling	Positive regulation; regulation; negative regulation	Furthermore, up-regulation of SIRT1 in metastatic OSCCs significantly inhibited the migration and invasion abilities of OSCC cells, while concomitantly increasing the expression of E-cadherin, and decreasing the expressions of mesenchymal markers. Overexpression of SIRT1 in OSCC cells led to decreased levels of acetylated Smad4, and inhibition of TGF-β-induced signaling.
25420528	Breast Carcinoma	partner	N1IC	Negative correlation	SIRT1, N1IC, and Snail were all found to be highly expressed and an inverse correlation between SIRT1 and N1IC in breast cancer tissue.
25341037	Synovial Sarcoma	downstream	LC3II	Positive regulation	Using siRNA to knock down SIRT1 and SIRT2, we show that the expression of both proteins is crucial for the survival of rhabdomyosarcoma cells and that the loss of SIRT1 expression results in a decreased LC3II expression.
25281719	Ewing Sarcoma	upstream	NOTCH	Negative regulation	Restoration of NOTCH signaling caused growth arrest due to activation of the NOTCH effector HEY1, directly suppressing SIRT1 and thereby activating p53.
25281719	Ewing Sarcoma	downstream	p53	Negative regulation	Restoration of NOTCH signaling caused growth arrest due to activation of the NOTCH effector HEY1, directly suppressing SIRT1 and thereby activating p53.
25270091	Endometrial Carcinoma	downstream	SREBP1	Positive regulation	Knockdown of SIRT1 could downregulate expression of SREBP1 and suppress cell proliferation.
25172416	Pancreatic Carcinoma	upstream	miR-217	Negative regulation	Consistently, miR-217 was obviously down-regulated in CP, PC and TGF-β1 treated PC cells, while negatively correlated to its direct target SIRT1. Moreover, either ectopic expression of miR-217 or inhibition of SIRT1 remarkably induced mesenchymal to epithelial transition (MET) in TGF-β1 treated PC cells.
24959282	Lung Adenocarcinoma	partner	HIF1	Correlation	Immunohistochemical staining was performed to investigate Sirt1 expression in cancer cells in 125 consecutive resected cases of primary lung adenocarcinoma. Sirt1 expression was found to be increased in 26 (20.8%) of the 125 cases, which correlated significantly with five clinicopathological factors: Ki67 index, hypoxia-inducible factor 1 (HIF1) molecule expression, tumor-node-metastasis (TNM) classification, pulmonary vein invasion and lymphatic duct invasion.
24751483	Melanoma	downstream	p53	Regulation	SIRT1 appears to be acting through the activity of the tumor suppressor p53, which is not mutated in the majority of melanomas.
24338587	Hepatocellular Carcinoma	downstream	FXR; mTOR; BA	Positive regulation; regulation; regulation	Finally, we found that human hepatocellular carcinoma (HCC) samples have increased presence of SIRT1, which correlated with the absence of FXR, suggesting its oncogenic potential. We define SIRT1 as a key regulator of the regenerative response in the liver through posttranscriptional modifications that regulate the activity of FXR, histones, and mTOR. Moreover, our data suggest that SIRT1 contributes to liver tumorigenesis through dysregulation of BA homeostasis by persistent FXR deacetylation.
24127549	Prostate Carcinoma	downstream	H2A.Z	Negative regulation	Induced SIRT1 overexpression in prostate cancer cell lines resulted in almost complete absence of H2A.Z.
24107295	Gastric Carcinoma	downstream	Cyclin D1	Negative regulation	At the molecular level, SIRT1 inhibited the transcription of Cyclin D1 (CCND1), and inhibition of NF-κB in SIRT1-depleted cells rescued Cyclin D1 expression.
24035280	Gastroesophageal Junction Cancer	partner	E-cadherin	Negative correlation	SIRT1 and p300/CBP were negatively and positively correlated with the expression of E-cadherin and MLH1, respectively, in the cancer cases.
24009628	Colorectal Carcinoma	partner	DBC1; β-catenin; survivin	Association	Expression of SIRT1 was significantly related to DBC1 (p=0.001), β-catenin (p=0.001), and survivin (p=0.002), but not with p53.
23768087	Gastric Carcinoma	upstream	miR-204	Negative regulation	SIRT1 was defined as the target gene and elucidated the biological functions of miR-204 with a luciferase reporter assay and Western blot analysis. We verified that miR-204 levels were down-regulated and significantly associated with the up-regulation of SIRT1 mRNA levels in gastric cancer specimens.
23768087	Gastric Carcinoma	partner	LKB1	Collaboration	Our results suggest that down-regulation of miR-204 promotes gastric cancer cell invasion by activating the SIRT1-LKB1 pathway.
23728341	Hepatocellular Carcinoma	upstream	miR-29c	Negative regulation	Taken together, we demonstrated that miR-29c suppresses oncogenic SIRT1 by way of binding to 3'-untranslated region of SIRT1 mRNA causing translational inhibition in liver cancer cells
23542177	Hepatocellular Carcinoma	partner	CTGF	Positive correlation	In our experiments, we observed that the expression of SIRT1 is significantly upregulated in the tumor samples of the hepatocarcinoma patients, and SIRT1 mRNA level positively correlates with connective tissue growth factor (CTGF) mRNA level.
23542177	Hepatocellular Carcinoma	downstream	YAP2/TEAD4	Positive regulation	We then found that SIRT1 deacetylates YAP2 protein in HCC cells and SIRT1-mediated deacetylation increases the YAP2/TEAD4 association, leading to YAP2/TEAD4 transcriptional activation and upregulated cell growth in HCC cells.
23340254	Invasive Ductal Carcinoma	downstream	PI.3/PII; PI.4; estrogen-related receptorα	Regulation	Additionally, by chromatin immunoprecipitation, we demonstrate that SIRT1 occupies the promoter regions PI.3/PII and PI.4, and its inhibition leads to increased acetylation of estrogen-related receptorα, a transcription factor that positively regulates CYP19A1 transcription in epithelial cells.
23038275	Prostate Carcinoma	downstream	MMP2	Regulation	We show that SIRT1 associates and deacetylates MMP2 and SIRT1 regulates MMP2 expression by controlling MMP2 protein stability through the proteosomal pathway.
22986535	Thyroid Gland Carcinoma	downstream	c-MYC	Positive regulation	Based on mRNA expression analyses of pre-tumoral murine thyroids, we find that SIRT1 increases c-MYC transcriptional programs. Similarly, SIRT1 is overexpressed in human thyroid cancers and it is positively correlated with c-MYC protein levels. Finally, we show in cultured thyroid cancer cells that SIRT1 stabilizes c-MYC protein.
22340598	Chronic Myelogenous Leukemia	downstream	p53	Negative regulation	Activation of p53 via SIRT1 inhibition represents a potential approach to target CML LSC.
22149272	Colorectal Carcinoma	downstream	PER1; CaCo2	Positive regulation; negative regulation	SIRT1 overexpression induced PER1 upregulation in CaCo2 and downregulation in SW480 cells.
22146883	Hepatocellular Carcinoma	partner	α-fetoprotein; β-catenin	Positive correlation; association	SIRT1 overexpression was associated with higher α-fetoprotein level, higher tumor grade, and absence of β-catenin mutation.
21596753	Breast Carcinoma	upstream	miR-200	Positive regulation	These observations provide further evidence for a critical tumor suppressive role of the miR-200 family in breast epithelium in addition to identifying a novel regulatory mechanism, which may contribute to SIRT1 up-regulation in breast cancer.
21567102	Hepatocellular Carcinoma	partner	p53	Correlation	Expression of SIRT1 showed significant correlation with gender (p=0.023), serum AFP levels (p=0.030), viral infection (p=0.005) and p53 expression (p<0.021).
21555002	Chronic Myeloid Leukemia	downstream	EVI1	Regulation	Our results thus identify an EVI1-SIRT1 axis in the regulation of EVI1 activity suggesting a possible role of SIRT1 in EVI1 positive neoplasms.
21527554	Hepatocellular Carcinoma	downstream	TERT; PTOP	Positive regulation	SIRT1 silencing also caused telomere dysfunction-induced foci and nuclear abnormality that were clearly associated with reduced expressions of telomerase reverse transcriptase (TERT), and PTOP, which is a member of the shelter in complex.
20956937	Prostate Carcinoma	upstream	NAMPT	Positive regulation	In this study, we show that NAMPT is prominently overexpressed in human prostate cancer cells along with SIRT1. We demonstrate that in addition to modulating SIRT1 functions, the NAMPT inhibition reduces forkhead box, class 'O' (FOXO)3a protein expression and its downstream anti-oxidant genes catalase and manganese superoxide dismutase.
20412117	Breast Carcinoma	upstream	DBC1	Negative regulation	This suggests that the negative regulation of SIRT1 by DBC1 may retard tumorigenesis in breast tissue.